Entero Therapeutics (ENTO) 10-Q 23 May 22 2022 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2022	May 19, 2022
Document Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2022
Document Transition Report	false
Entity File Number	001-37853
Entity Registrant Name	First Wave BioPharma, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	46-4993860
Entity Address, Address Line One	777 Yamato Road, Suite 502
Entity Address, City or Town	Boca Raton
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33431
City Area Code	561
Local Phone Number	589-7020
Title of 12(b) Security	Common stock, par value $0.0001 per share
Trading Symbol	FWBI
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		21,635,338
Entity Central Index Key	0001604191
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2022
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Current Assets:
Cash and cash equivalents	$ 5,694,988	$ 8,248,684
Other receivables	28,055
Prepaid expenses	827,128	1,176,268
Total Current Assets	6,550,171	9,424,952
Property, equipment, and leasehold improvements, net	65,793	73,110
Other Assets:
Goodwill	1,862,069	1,911,705
Operating lease right-of-use assets	313,009	336,197
Deposits	34,397	44,012
Total Other Assets	2,209,475	2,291,914
Total Assets	8,825,439	11,789,976
Current Liabilities:
Accounts payable	3,449,928	2,707,731
Accrued expenses	717,514	393,253
Accrued dividend payable	556,153	465,361
Note payable.	402,766	641,236
Operating lease liabilities	70,784	77,989
Payable related to acquisition - current	9,000,000	8,000,000
Other current liabilities	18,575	14,818
Total Current Liabilities	14,215,720	12,300,388
Non-current operating lease liabilities	264,460	311,138
Payable related to acquisition - long term	3,585,044	7,000,000
Total Liabilities	18,065,224	19,611,526
Commitments and Contingencies
Stockholders' Deficit:
Common stock - Par value $0.0001 per share; 50,000,000 shares authorized; 21,548,835 and 14,855,848 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively	2,154	1,485
Additional paid-in capital	155,571,487	147,305,147
Accumulated deficit	(163,530,886)	(153,904,047)
Accumulated other comprehensive loss	(1,282,540)	(1,224,135)
Total Stockholders' Deficit	(9,239,785)	(7,821,550)
Total Liabilities and Stockholders' Deficit	8,825,439	11,789,976
Series B Preferred Stock [Member]
Stockholders' Deficit:
Preferred stock	0	0
Series C Preferred Stock [Member]
Stockholders' Deficit:
Preferred stock	$ 0	$ 0

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parentheticals) - $ / shares	Mar. 31, 2022	Dec. 31, 2021
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	50,000,000	50,000,000
Common stock, shares issued (in shares)	21,548,835	14,855,848
Common stock, shares outstanding (in shares)	21,548,835	14,855,848
Preferred stock, par value (in dollars per share)	$ 0.0001
Preferred stock, shares authorized (in shares)	10,000,000
Series B Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	5,194.81	5,194.81
Preferred stock, shares issued (in shares)	645.21	662.25
Preferred stock, shares outstanding (in shares)	645.20	662.25
Series C Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	57,000	57,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Operating expenses:
Research and development expenses	$ 4,976,517	$ 2,516,027
General and administrative expenses	4,405,555	5,697,514
Total operating expenses	9,382,072	8,213,541
Loss from operations	(9,382,072)	(8,213,541)
Other (expense) income:
Interest expense	(5,605)	(5,144)
Interest income	139	403
Other expense	(239,301)
Change in fair value of liability		532,653
Total other (expense) income	(244,767)	527,912
Net loss	(9,626,839)	(7,685,629)
Other comprehensive loss:
Foreign currency translation adjustment	(58,405)	(134,797)
Total comprehensive loss	(9,685,244)	(7,820,426)
Net loss	(9,626,839)	(7,685,629)
Deemed dividend on preferred stock		(4,507,125)
Deemed dividend on preferred stock exchanges		(17,584,048)
Deemed dividend on warrant modification	(594,975)
Preferred stock dividends	(90,792)	(204,382)
Net loss applicable to common shareholders	$ (10,312,606)	$ (29,981,184)
Basic weighted average number of shares outstanding	15,544,679	5,534,813
Diluted weighted average number of shares outstanding	15,544,679	5,534,813
Loss per share, Basic	$ (0.66)	$ (5.42)
Loss per share, Diluted	$ (0.66)	$ (5.42)

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Stockholders' Deficit (Unaudited) - USD ($)	Common Stock, Pre-funded Warrants, and Cash Warrants [Member]Convertible preferred stock (1)Series B Convertible Preferred Stock [Member]	Common Stock, Pre-funded Warrants, and Cash Warrants [Member]Common Stock [Member]	Common Stock, Pre-funded Warrants, and Cash Warrants [Member]Additional Paid-in Capital [Member]	Common Stock, Pre-funded Warrants, and Cash Warrants [Member]Retained Earnings [Member]	Common Stock, Pre-funded Warrants, and Cash Warrants [Member]AOCI Attributable to Parent [Member]	Common Stock, Pre-funded Warrants, and Cash Warrants [Member]	Conversion of Series B Preferred Shares Into Common Stock [Member]Convertible preferred stock (1)Series B Convertible Preferred Stock [Member]	Conversion of Series B Preferred Shares Into Common Stock [Member]Common Stock [Member]	Conversion of Series B Preferred Shares Into Common Stock [Member]Additional Paid-in Capital [Member]	Conversion of Series B Preferred Shares Into Common Stock [Member]Retained Earnings [Member]	Conversion of Series B Preferred Shares Into Common Stock [Member]AOCI Attributable to Parent [Member]	Conversion of Series B Preferred Shares Into Common Stock [Member]	Series B Preferred Stock Converted into Common Stock [Member]	Convertible preferred stock (1)Series B Convertible Preferred Stock [Member]	Convertible preferred stock (1)Series C Convertible Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Balance at the beginning (in shares) at Dec. 31, 2020														2,774	0	3,115,031
Balance at the beginning at Dec. 31, 2020														$ 0	$ 0	$ 3,115	$ 93,834,936	$ (95,366,198)	$ (1,112,546)	$ (2,640,693)
Issuance of Series C preferred stock and warrants for cash, net of offering costs (in shares)															10,670
Issuance of Series C preferred stock and warrants for cash, net of offering costs														0	$ 0	0	7,105,167	0	0	7,105,167
Issuance of Series C preferred stock to settle liability arising from acquisition (in shares)															3,290
Issuance of Series C preferred stock to settle liability arising from acquisition														0	$ 0	0	2,467,648	0	0	2,467,648
Beneficial conversion feature of Series C preferred stock														0	0	0	4,507,125	0	0	4,507,125
Deemed dividend on preferred stock														$ 0	$ 0	0	(4,507,125)	0	0	(4,507,125)
Issuance of Series C preferred stock upon exchange of Series B preferred stock (in shares)														(1,306)	13,500
Issuance of Series C preferred stock upon exchange of Series B preferred stock														$ 0	$ 0	0	(1,009)	0	0	(1,009)
Warrants issued in connection with exchange of Series B preferred stock into Series C preferred stock														0	0	0	17,585,057	0	0	17,585,057
Deemed dividend of Series B preferred stock														$ 0	0	$ 0	(17,584,048)	0	0	(17,584,048)
Common stock issued upon conversion of Series B preferred stock (in shares)														(259)		258,278
Common stock issued upon conversion of Series B preferred stock														$ 0	0	$ 258	(258)	0	0	0
Deemed dividend on preferred stock																				(4,507,125)
Issuance of stock upon conversion of securities													$ 2,000,000
Deemed dividend on preferred stock exchanges																				(17,584,048)
Dividends on preferred stock														0	$ 0	$ 0	(204,382)	0	0	(204,382)
Common stock and pre-funded warrants issued upon conversion of Series C preferred stock (in shares)															(27,460)	2,561,544
Common stock and pre-funded warrants issued upon conversion of Series C preferred stock														0	$ 0	$ 2,562	(2,559)	0	0	3
Issuance of common stock, pre-funded warrants and warrants for cash, net of offering costs (in shares)																580,000
Issuance of common stock, pre-funded warrants and warrants for cash, net of offering costs														0	0	$ 580	9,058,710	0	0	9,059,290
Common stock issued upon exercise of warrants (in shares)																912,807
Common stock issued upon exercise of warrants														0	0	$ 913	4,622,929	0	0	4,623,842
Issuance of common stock in connection with settlement with former investment bank (in shares)																7,500
Issuance of common stock in connection with settlement with former investment bank														0	0	$ 7	94,492	0	0	94,499
Common stock and warrants issued to consultants														0	0	$ 58	944,441	0	0	944,499
Common stock and warrants issued to consultants (in shares)																57,530
Stock-based compensation														0	0	$ 0	772,240	0	0	772,240
Foreign currency translation adjustment														0	0	0	0	0	(134,797)	(134,797)
Net loss														$ 0	$ 0	$ 0	0	(7,685,629)	0	(7,685,629)
Balance at the end (in shares) at Mar. 31, 2021														1,209	0	7,492,690
Balance at the end at Mar. 31, 2021														$ 0	$ 0	$ 7,493	118,693,364	(103,051,827)	(1,247,343)	14,401,687
Balance at the beginning (in shares) at Dec. 31, 2020														2,774	0	3,115,031
Balance at the beginning at Dec. 31, 2020														$ 0	$ 0	$ 3,115	93,834,936	(95,366,198)	(1,112,546)	(2,640,693)
Balance at the end (in shares) at Dec. 31, 2021														662		14,855,848
Balance at the end at Dec. 31, 2021														$ 0		$ 1,485	147,305,147	(153,904,047)	(1,224,135)	(7,821,550)
Balance at the beginning (in shares) at Dec. 31, 2020														2,774	0	3,115,031
Balance at the beginning at Dec. 31, 2020														$ 0	$ 0	$ 3,115	93,834,936	(95,366,198)	(1,112,546)	(2,640,693)
Balance at the end (in shares) at Mar. 31, 2022														645		21,548,835
Balance at the end at Mar. 31, 2022														$ 0		$ 2,154	155,571,487	(163,530,886)	(1,282,540)	(9,239,785)
Balance at the beginning (in shares) at Dec. 31, 2021														662		14,855,848
Balance at the beginning at Dec. 31, 2021														$ 0		$ 1,485	147,305,147	(153,904,047)	(1,224,135)	(7,821,550)
Deemed dividend of Series B preferred stock														0		$ 0	(90,792)	0	0	(90,792)
Warrant modification																	594,975			594,975
Deemed dividend on warrant modification																	(594,975)			(594,975)
Issuance of stock and warrants for cash, net of offering costs (in shares)		1,650,000
Issuance of stock and warrants for cash, net of offering costs	$ 0	$ 165	$ 7,971,926	$ 0	$ 0	$ 7,972,091
Exercise of pre-funded warrants into common stock (in shares)																4,848,195
Exercise of pre-funded warrants into common stock														0		$ 485	47,997	0	0	48,482
Issuance of stock upon conversion of securities (in shares)							(17)	104,735
Issuance of stock upon conversion of securities							$ 0	$ 10	$ (10)	$ 0	$ 0	$ 0
Common stock and warrants issued to consultants (in shares)																90,057
Common stock and warrants issued to consultants														0		$ 9	118,990	0	0	118,999
Stock-based compensation														0		0	218,229	0	0	218,229
Foreign currency translation adjustment														0		0	0	0	(58,405)	(58,405)
Net loss														$ 0		$ 0	0	(9,626,839)	0	(9,626,839)
Balance at the end (in shares) at Mar. 31, 2022														645		21,548,835
Balance at the end at Mar. 31, 2022														$ 0		$ 2,154	$ 155,571,487	$ (163,530,886)	$ (1,282,540)	$ (9,239,785)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Cash flows from operating activities:
Net loss	$ (9,626,839)	$ (7,685,629)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	7,317	1,021
Amortization		131,887
Change in right-of-use assets	23,188	(4,855)
Stock-based compensation	218,229	772,240
Common stock and warrants granted to consultants	118,999	1,038,998
Changes in assets and liabilities:
Other receivables	(28,055)	17,592
Prepaid expenses	349,140	613,076
Lease liabilities	(53,883)	11,654
Deposits	9,615	(1,356)
Accounts payable and accrued expenses	1,066,458	53,938
Accrued dividends payable		204,382
Other liabilities	3,757	(226,342)
Net cash used in operating activities	(7,912,074)	(5,073,394)
Cash flows from financing activities:
Proceeds from issuance of preferred stock, net		7,105,167
Proceeds from issuance of common stock, net	7,972,091	9,059,290
Proceeds from exercise of warrants	48,482	4,623,842
Payment made related to acquisition agreement	(2,414,956)
Payment made related to license agreement		(9,532,353)
Repayments of note payable	(238,470)	(205,323)
Net cash provided by financing activities	5,367,147	11,050,623
Net (decrease) increase in cash	(2,544,927)	5,977,229
Effect of exchange rate changes on cash	(8,769)	(13,738)
Cash and cash equivalents, beginning balance	8,248,684	6,062,141	$ 6,062,141
Cash and cash equivalents, ending balance	5,694,988	12,025,632	$ 8,248,684
Supplemental disclosures of cash flow information:
Cash paid for interest		5,144
Non-cash investing and financing activities:
Deemed dividend on preferred stock issuances		(4,507,125)
Deemed dividend on preferred stock exchanges		(17,584,048)
Deemed dividend on warrant modification	(594,975)
Accrued dividends on preferred stock	(90,792)	(204,382)
Common stock issued upon conversion of preferred stock	$ (10)
Issuance of Series C preferred stock to settle liability arising from acquisition		$ 2,467,648

The Company and Basis of Presen

The Company and Basis of Presentation	3 Months Ended
	Mar. 31, 2022
The Company and Basis of Presentation
The Company and Basis of Presentation	Note 1 - The Company and Basis of Presentation The Company First Wave BioPharma, Inc. (“ First Wave GI The Company is currently focused on developing its pipeline of gut-restricted GI clinical drug candidates, including the biologic adrulipase (formerly MS1819), a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients, and niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties.The Company’s adrulipase programs are focused on the development of an oral, non-systemic, biologic capsule for the treatment of exocrine pancreatic insufficiency (“ EPI CF CP IBD The Company is developing its product candidates for a host of GI diseases where there are significant unmet clinical needs and limited therapeutic options, resulting in painful, life threatening and discomforting consequences for patients. Since its inception, the Company has devoted substantially all its efforts to research and development, business development, and raising capital, and has financed its operations through issuance of common stock, convertible preferred stock, convertible debt, and other debt/equity instruments. Risks and Uncertainties The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development and regulatory success, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations, and ability to secure additional capital to fund clinical trials and operations. The Company has implemented business continuity plans designed to address and mitigate the impact of the COVID-19 pandemic on its business. The extent to which the ongoing COVID-19 pandemic impacts the Company’s business, clinical development and regulatory efforts, corporate development objectives and the value of and market for its Common Stock, will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time, such as the ultimate duration of the pandemic, travel restrictions, quarantines, social distancing and business closure requirements in the U.S., Europe, Asia and other countries, and the effectiveness of actions taken globally to contain and treat the disease. The global economic slowdown, the overall disruption of global healthcare systems and the other risks and uncertainties associated with the pandemic could have a material adverse effect on the Company’s business, financial condition, results of operations and growth prospects. In February 2022, the Russian Federation and Belarus commenced a military action with the country of Ukraine. As a result of this action, various nations, including the United States, have instituted economic sanctions against the Russian Federation and Belarus. Further, the impact of this action and related sanctions on the world economy are not determinable as of the date of these financial statements and the specific impact on the Company's financial condition, results of operations, and cash flows is also not determinable as of the date of these financial statements. In addition, the Company is subject to other challenges and risks specific to its business and its ability to execute on its strategy, as well as risks and uncertainties common to companies in the biotechnology and pharmaceutical industries with development and commercial operations, including, without limitation, risks and uncertainties associated with: obtaining regulatory approval of its drug candidates; delays or problems in the manufacture and supply of its drug candidates, loss of single source suppliers or failure to comply with manufacturing regulations; identifying, acquiring or in-licensing additional products or drug candidates; pharmaceutical product development and the inherent uncertainty of clinical success; and the challenges of protecting and enhancing our intellectual property rights; complying with applicable regulatory requirements. In addition, to the extent the ongoing COVID-19 pandemic adversely affects the Company’s business and results of operations, it may also have the effect of heightening many of the other risks and uncertainties discussed above. Principles of Consolidation The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“ GAAP In our opinion, the accompanying unaudited interim condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to present fairly our financial position, results of operations, and cash flows. The consolidated balance sheet at December 31, 2021, has been derived from audited financial statements of that date. The unaudited interim condensed consolidated results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain information and footnote disclosure normally included in financial statements prepared in accordance with GAAP have been omitted pursuant to instructions, rules, and regulations prescribed by the SEC. The Company believes that the disclosures provided herein are adequate to make the information presented not misleading when these unaudited interim condensed consolidated financial statements are read in conjunction with the audited financial statements and notes previously distributed in our Annual Report Form 10-K for the year ended December 31, 2021, filed with the SEC on March 31, 2022 (as amended on Form 10-K/A filed with the SEC on May 10, 2022). Going Concern Uncertainty The accompanying unaudited interim condensed consolidated financial statements have been prepared as if the Company will continue as a going concern. The Company has incurred significant operating losses and negative cash flows from operations since inception. On March 31, 2022, the Company had cash and cash equivalents of approximately $ 5.7 Without adequate working capital, the Company may not be able to meet its obligations and continue as a going concern. These conditions raise substantial doubt about the Company’s ability to continue as a going concern one year from the date these financial statements are issued. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Significant Accounting Policies

Significant Accounting Policies and Recent Accounting Pronouncements	3 Months Ended
	Mar. 31, 2022
Significant Accounting Policies and Recent Accounting Pronouncements
Significant Accounting Policies and Recent Accounting Pronouncements	Note 2 - Significant Accounting Policies and Recent Accounting Pronouncements Use of Estimates The accompanying unaudited condensed consolidated financial statements are prepared in conformity with GAAP and include certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements (including goodwill and intangible assets), and the reported amounts of revenue and expense during the reporting period, including contingencies. Accordingly, actual results may differ from those estimates. Reverse Stock Split On September 13, 2021, the Company effected a reverse stock split, whereby every ten shares of the Company’s issued and outstanding common stock was converted automatically into one issued and outstanding share of common stock, with a corresponding 1-for-10 reduction in the number of authorized shares of common stock, but without any change in the par value per share. All share and per share amounts have been retroactively restated to reflect the reverse stock split. Reclassifications Certain prior period balance sheet amounts have been reclassified to conform to the fiscal 2022 presentation. Cash and Cash Equivalents The Company considers all highly liquid investments with maturities of three months or less from date of purchase to be cash equivalents. All cash balances were highly liquid on March 31, 2022, and December 31, 2021, respectively. Concentrations of Credit Risk Financial instruments that potentially expose the Company to concentrations of credit risk consist of cash. The Company primarily maintains its cash balances with financial institutions in federally insured accounts in the U.S. The Company may from time to time have cash in banks in excess of FDIC insurance limits. On March 31, 2022, and December 31, 2021, the Company had approximately $4.9 million and $7.5 million, respectively, in one account in the U.S. in excess of these limits. The Company has not experienced any losses to date resulting from this practice. The Company also has exposure to foreign currency risk as its subsidiary in France has a functional currency in Euros. Fair Value Measurements The Company follows Accounting Standards Codification ( ASC ( ASC 820 As a basis for considering such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows: Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities; Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions, which reflect those that a market participant would use. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, an instrument’s level within the fair value hierarchy is based on the lowest level of input that is significant to the overall fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the financial instrument. The Company recognizes transfers between levels as if the transfers occurred on the last day of the reporting period. Foreign Currency Translation The Company’s foreign subsidiary has operations denominated in a foreign currency, and assets and liabilities are translated to U.S. dollars, which is the functional currency, at period end exchange rates. Income and expense items are translated at average rates of exchange prevailing during the periods presented. Gains and losses from translation adjustments are accumulated in a separate component of stockholders’ equity. Goodwill and Intangible Assets Goodwill represents the excess of the purchase price of the acquired business over the fair value of amounts assigned to assets acquired and liabilities assumed. Goodwill and other intangible assets with indefinite useful lives are reviewed for impairment annually or more frequently if events or circumstances indicate impairment may be present. Any excess in carrying value over the estimated fair value is charged to results of operations. The Company has not Intangible assets subject to amortization consist of in process research and development, license agreements, and patents reported at the fair value at date of the acquisition less accumulated amortization. Amortization expense is provided using the straight-line method over the estimated useful lives of the assets as follows: Patents 7.2 years The carrying amounts of finite-lived intangible assets are evaluated for recoverability whenever events or changes in circumstances indicate that the Company may be unable to recover the asset’s carrying amount. Given changes in the projected usage of the patents, the Company recognized impairment charges of approximately $2.4 million at December 31, 2021. Impairment of Long-Lived Assets The Company periodically evaluates its long-lived assets for potential impairment in accordance with ASC Topic 360, Property, Plant and Equipment ( ASC 360 Leases Leases are recorded on the balance sheet as right of use assets and lease obligations. Research and Development Research and development costs are charged to operations when incurred and are included in operating expense, except for goodwill related to patents. Research and development costs consist principally of compensation of employees and consultants that perform the Company’s research activities, payments to third parties for preclinical and non-clinical activities, expenses with clinical research organizations (“ CROs CDMOs CMC Research and Development – On December 31, 2020, the Company entered into a license agreement (the “ FWB License Agreement On September 13, 2021, the Company completed its acquisition of FWB, which the Company concluded should be accounted for as an asset acquisition rather than a business combination under ASC 805, Business Combinations. The merger was accounted for as an asset acquisition because substantially all the fair value of the assets being acquired are concentrated in a single asset – intellectual property, which does not constitute a business. The former FWB stockholders are also entitled to (i) up to $ 207.0 million of cash milestone payments contingent upon the achievement of specified development, regulatory and sales goals for the use of the acquired assets, and (ii) certain revenue-sharing. During the year ended December 31, 2021, the Company achieved one development milestone pursuant to the FWB License Agreement totaling $1.0 million, which was expensed in research and development. During the year ended December 31, 2021, the Company achieved one development milestone pursuant to the Merger Agreement totaling $2.0 million, which was expensed in research and development. Depending on the status of development at the time a contingent payment is recognized the Company may determine that the payment should be expensed as research and development or be capitalized as an intangible asset. This determination will be based on the facts and circumstances that exist at the time a contingent payment is recognized (See Note 4 for the discussion on the quarter ended March 31, 2022 milestones). Due to the recent topline results of the Phase 2 RESERVOIR COVID-19 GI clinical trial (see Note 1), the Company has suspended payments to the former FWB stockholders and is seeking to renegotiate its obligations to the former FWB stockholders. On May 19, 2022, the Representative filed a complaint against the Company (see Note 17 – The FWB Action Stock-Based Compensation The Company’s board of directors (the “ Board 2014 Plan 2020 Plan ASC 718 For awards with performance conditions that affect their vesting, such as the occurrence of certain transactions or the achievement of certain operating or financial milestones, recognition of fair value of the award occurs when vesting becomes probable. The Company estimates the grant date fair value of stock option awards using the Black-Scholes option-pricing model. The use of the Black-Scholes option-pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the Common Stock consistent with the expected life of the option, risk-free interest rates and expected dividend yields of the Common Stock. Recent Accounting Pronouncements In August 2020, the Financial Accounting Standards Board (the “ FASB SEC In June 2016, the FASB issued accounting pronouncement ASU 2016-13 – Measurement of Credit Losses on Financial Statements. The new standard requires that expected credit losses relating to financial assets measured on an amortized cost basis and available-for-sale debt securities be recorded through an allowance for credit losses. It also limits the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and also requires the reversal of previously recognized credit losses if fair value increases. In November 2019, the FASB issued ASU 2019-10 – Financial Instruments – Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates, which amended the effective date for certain companies. The standard is effective for public companies eligible to be smaller reporting companies for annual and interim periods beginning after December 15, 2022. Early adoption is available. The Company is currently evaluating the potential impact ASU 2016-13, and related updates, will have on its consolidated financial statements and disclosures. The Company has evaluated other recently issued accounting pronouncements and has concluded that the impact of recently issued standards that are not yet effective will not have a material impact on the Company’s financial position or results of operations upon adoption.

Fair Value Disclosures

Fair Value Disclosures	3 Months Ended
	Mar. 31, 2022
Fair Value Disclosures
Fair Value Disclosures	Note 3 - Fair Value Disclosures Fair value is the price that would be received from the sale of an asset or paid to transfer a liability assuming an orderly transaction in the most advantageous market at the measurement date. U.S. GAAP establishes a hierarchical disclosure framework that prioritizes and ranks the level of observability of inputs used in measuring fair value. The fair value of the Company’s financial instruments are as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair Value Measured at Reporting Date ​ ​ ​ ​ ​ ​ ​ ​ Using ​ ​ ​ ​ ​ Carrying ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Amount Level 1 Level 2 Level 3 Fair Value March 31, 2022 (unaudited): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Money market funds ​ $ 501,546 ​ $ 501,546 ​ $ — ​ $ — ​ $ 501,546 Note payable ​ 402,766 ​ — ​ 402,766 ​ — ​ 402,766 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2021: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Money market funds ​ ​ 501,607 ​ ​ 501,607 ​ ​ — ​ ​ — ​ ​ 501,607 Note payable ​ $ 641,236 ​ $ — ​ $ 641,236 ​ $ — ​ $ 641,236 ​ At March 31, 2022 and December 31, 2021, the Company had no other assets or liabilities that are subject to fair value methodology and estimation in accordance with U.S. GAAP.

Asset Acquisition

Asset Acquisition	3 Months Ended
	Mar. 31, 2022
Asset Acquisition
Asset Acquisition	Note 4 – Asset Acquisition The Asset Acquisition On September 13, 2021, the Company completed its acquisition of FWB, in accordance with the terms of an Agreement and Plan of Merger dated as of September 13, 2021 (the “ Merger Agreement Merger Sub Merger At the effective time of the Merger, the former FWB stockholders received an applicable pro rata share of (i) $3.0 million in cash and (ii) 624,025 shares of the Common Stock (equivalent to cash of $4.0 million). The remaining non-contingent purchase price was payable to the former FWB stockholders on a pro rata basis upon the Company’s payment of (i) $8.0 million in cash, payable within 45 days of the Merger, and (ii) $7.0 million in cash, payable by March 31, 2022 for a total purchase price of $22.0 million. On October 29, 2021, Fortis Advisors LLC, the hired representative (in such capacity, the “ Representative On November 15, 2021, the Company reached an agreement (the “ Settlement Agreement The former FWB stockholders are entitled to up to a total of $207 million of cash milestone payments contingent upon the achievement of specified development, regulatory and sales goals relating to the use of the acquired assets. All milestone payments will be payable in cash, provided that 25% of the milestone payments attributable to a certain IBD indications may be payable in Common Stock, at the option of the Company. In addition, the former FWB stockholders are entitled to 10% of certain specified revenue received by the Company from any third-party with a pre-existing niclosamide development program relating to COVID. During the quarter ended March 31, 2022 the Company paid an aggregate of $2.4 million in cash towards the purchase price. During the year ended December 31, 2021, the Company paid an aggregate of $7.0 million (in cash and shares) towards the purchase price and $2.0 million in milestone payments. Due to the recent topline results of the Phase 2 RESERVOIR COVID-19 GI clinical trial (see Note 1), the Company has suspended payments to the former FWB stockholders and is seeking to renegotiate its obligations to the former FWB stockholders. On May 19, 2022, the Representative filed a complaint against the Company (see Note 17 – The FWB Action Accounting Treatment The Company concluded that the Merger should be accounted for as an asset acquisition under ASC 805 because substantially all the fair value of the assets being acquired are concentrated in a single asset - intellectual property, which does not constitute a business. Because the acquired intellectual property has not received regulatory approval, the $21.3 million non-contingent purchase price was immediately expensed in the Company’s statements of operations as research and development – intellectual property acquired in the year ended December 31, 2021. The $0.9 million of transaction expenses paid at closing were classified in general and administrative expenses in the year ended December 31, 2021. The Common Stock issued for the asset acquisition was valued at $4.0 million, which is equal to the 624,025 common shares issued multiplied by $6.41 per share. The potential milestone payments and revenue share are not yet considered probable, therefore no milestone payments have been accrued as of March 31, 2022. Depending on the status of development at the time a contingent payment is recognized the Company may determine that the payment should be expensed as research and development or be capitalized as an intangible asset. This determination will be based on the facts and circumstances that exist at the time a contingent payment is recognized.

Property, Equipment and Leaseho

Property, Equipment and Leasehold Improvements	3 Months Ended
	Mar. 31, 2022
Property, Equipment and Leasehold Improvements
Property, Equipment and Leasehold Improvements	Note 5 – Property, Equipment and Leasehold Improvements Property, equipment, and leasehold improvements consisted of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, ​ ​ ​ ​ 2022 December 31, ​ ​ (unaudited) ​ 2021 Computer equipment and software ​ $ 11,540 ​ $ 11,540 Office equipment ​ 48,278 ​ 48,278 Leasehold improvements ​ 28,000 ​ 28,000 Total property, plant, and equipment ​ 87,818 ​ 87,818 Less accumulated depreciation ​ (22,025) ​ (14,708) Property, plant and equipment, net ​ $ 65,793 ​ $ 73,110 ​ Depreciation expense for the three months ended March 31, 2022 and 2021 was approximately $7,300

Intangible Assets and Goodwill

Intangible Assets and Goodwill	3 Months Ended
	Mar. 31, 2022
Intangible Assets and Goodwill
Intangible Assets and Goodwill	Note 6 – Intangible Assets and Goodwill Patents Pursuant to the Mayoly asset purchase agreement entered in March 2019 (see Note 13), in which the Company purchased all remaining rights, title and interest in and to adrulipase from Mayoly, the Company recorded Patents in the amount of approximately $3.8 million as follows: ​ ​ ​ ​ ​ Common stock issued at signing to Mayoly $ 1,740,959 Due to Mayoly at December 31, 2019 ​ 449,280 Due to Mayoly at December 31, 2020 ​ 393,120 Assumed Mayoly liabilities and forgiveness of Mayoly debt ​ 1,219,386 ​ ​ $ 3,802,745 ​ Intangible assets are as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, ​ ​ ​ ​ 2022 December 31, ​ ​ (unaudited) ​ 2021 Patents ​ $ — ​ $ 3,802,745 Less accumulated amortization ​ — ​ (1,450,757) Intangible asset impairment ​ — ​ (2,351,988) Patents, net ​ $ — ​ $ — ​ Amortization expense was approximately $132,000 for the three months ended March 31, 2021. During the year ended December 31, 2021, the Company recorded impairment charges of approximately $2.4 million related to patents that the Company determined were no longer sufficient for the commercialization of adrulipase. Goodwill is as follows: ​ ​ ​ ​ ​ ​ Goodwill Balance on January 1, 2021 ​ $ 2,054,048 Foreign currency translation ​ (142,343) Balance on December 31, 2021 ​ 1,911,705 Foreign currency translation ​ (49,636) Balance on March 31, 2022 (unaudited) ​ $ 1,862,069 ​

Accrued Expenses

Accrued Expenses	3 Months Ended
	Mar. 31, 2022
Accrued Expenses
Accrued Expenses	Note 7 - Accrued Expenses Accrued expenses consisted of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, ​ ​ ​ ​ 2022 December 31, ​ ​ (unaudited) ​ 2021 Professional fees ​ $ 443,030 ​ $ 15,000 Clinical trials ​ ​ 147,842 ​ ​ — Consulting fees ​ ​ 109,260 ​ ​ 104,100 Payroll and benefits ​ ​ 17,382 ​ ​ 274,153 Total accrued expenses ​ $ 717,514 ​ $ 393,253 ​

Note Payable

Note Payable	3 Months Ended
	Mar. 31, 2022
Note Payable
Note Payable	Note 8 – Note Payable Directors and Officer ’ s Liability Insurance On November 30, 2021, the Company entered into a 9-month

Other Liabilities

Other Liabilities	3 Months Ended
	Mar. 31, 2022
Other Liabilities
Other Liabilities	Note 9 - Other Liabilities Other liabilities consisted of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, ​ ​ ​ ​ 2022 December 31, ​ ​ (unaudited) ​ 2021 Current ​ ​ Lease liabilities ​ $ 70,784 ​ $ 77,989 Other liabilities ​ 18,575 ​ 14,818 Liabilities related to Merger consideration ​ 9,000,000 ​ 8,000,000 Total other current liabilities ​ $ 9,089,359 ​ $ 8,092,807 Long-term ​ ​ Lease liabilities ​ $ 264,460 ​ $ 311,138 Liabilities related to Merger consideration ​ 3,585,044 ​ 7,000,000 Total other long-term liabilities ​ $ 3,849,504 ​ $ 7,311,138 ​

Capital Stock

Capital Stock	3 Months Ended
	Mar. 31, 2022
Capital Stock
Capital Stock	Note 10 – Common Stock and Preferred Stock The Company’s certificate of incorporation, as amended and restated, (the “ Charter On September 13, 2021, the Company effected a reverse stock split, whereby every ten shares of the Company’s issued and outstanding common stock was converted automatically into one issued and outstanding share of common stock, with a corresponding 1-for-10 reduction in the number of authorized shares of common stock, but without any change in the par value per share. All share and per share amounts have been retroactively restated to reflect the reverse stock split. The Company had 21,548,835 and 14,855,848 shares of its Common Stock issued outstanding The Company had approximately 645.21 and 662.25 shares of Series B preferred stock issued outstanding The Company had 0 shares of Series C preferred stock issued and outstanding on March 31, 2022 and December 31, 2021, respectively. Series B Preferred Stock Waiver Agreements Between February 1 and February 7, 2022, the Company entered into waiver agreements (the “ Waiver Series B Preferred Stock Pursuant to the Series B Preferred Stock Certificate of Designations (the “ Series B Certificate of Designations Subsequent Financing Series B Exchange Right The Company entered into Waivers with holders of approximately $2.88 million of stated value of Series B Preferred Stock. The Company also entered into Waivers with Company insiders holding approximately $0.474 million of stated value of Series B Preferred Stock for which the Company did not pay a waiver fee. The cash waivers paid of approximately $0.233 million were recorded as other expense on the Company’s condensed consolidated statements of operations for the three months ending March 31, 2022. Equity Line with Lincoln Park In November 2019, the Company entered into a purchase agreement (the “ Equity Line Agreement Lincoln Park Registration Rights Agreement Equity Line Commitment Shares The remaining shares of Common Stock that may be issued under the Equity Line Agreement may be sold by the Company to Lincoln Park at the Company’s discretion from time-to-time over a 30-month There is approximately $14.0 million of availability left for issuance pursuant to the Equity Line Agreement. The Company has not issued At The Market Agreement with H.C. Wainwright On May 26, 2021, the Company entered into an At The Market Offering Agreement (the “ ATM Agreement Wainwright Common Stock Issuances Q1 2022 Issuances During the three months ended March 31, 2022, the Company completed a registered direct offering (the “ March 2022 Offering March 2022 Warrants March 2022 Placement Agent Warrants During the three months ended March 31, 2022, the Company issued an aggregate of 4,848,195 shares of Common Stock upon the conversion of pre-funded warrants issued at a par value of $0.01 (See Note 11). During the three months ended March 31, 2022, the Company issued an aggregate of 104,735 shares of Common Stock and accompanying Series C warrant upon the exchange of an aggregate of 17.05 shares of Series B Preferred Stock with a stated value of approximately $131,000 plus accrued dividends of approximately $14,000. The Series C warrants have an exercise price of $1.26 per share and will be exercisable for five years from the issuance date. During the three months ended March 31, 2022, the Company issued an aggregate of 90,057 shares of its Common Stock to consultants with a grant date fair value of approximately $119,000 for investor relations services provided, which was recorded as stock-based compensation and included as part of general and administrative expense. Q1 2021 Issuances During the three months ended March 31, 2021, the Company issued an aggregate of 57,530 shares of its Common Stock to consultants with a grant date fair value of approximately $891,000 for investor relations services provided, which was recorded as stock-based compensation and included as part of general and administrative expense. During the three months ended March 31, 2021, the Company issued an aggregate 7,500 shares of its Common Stock with a grant date fair value of approximately $94,000 in connection with the settlement with our former investment bank, which was recorded as stock-based compensation and included as part of general and administrative expense. During the three months ended March 31, 2021, the Company issued an aggregate of 2,561,544 shares of Common Stock upon the conversion of an aggregate of 2,746 shares of Series C Convertible Preferred Stock with a stated value of approximately $20.6 million plus accrued dividends of approximately $76,000. During the three months ended March 31, 2021, the Company issued an aggregate of 912,807 shares of Common Stock upon the exercise of an aggregate of 919,752 investor warrants, including an aggregate of 399,187 pre-funded warrants (See Note 11). During the three months ended March 31, 2021, the Company issued an aggregate of 258,278 shares of Common Stock upon the conversion of an aggregate of 26 shares of Series B Preferred Stock with a stated value of approximately $2.0 million plus accrued dividends of approximately $3,000. During the three months ended March 31, 2021, the Company completed a registered direct offering (the “ March 2021 Offering March 2021 Warrants March 2021 Placement Agent Warrants Q1 2021 Series C Purchase Agreement During the three months ended March 31, 2021, the Company closed on a securities purchase agreement (the “ Series C Purchase Agreement January 2021 Registered Direct Offering Concurrently with the January 2021 Registered Direct Offering, in a private placement offering pursuant to the Series C Purchase Agreement (the “ January 2021 Private Placement January 2021 Investor Warrants The net proceeds to the Company from the offerings described above (the “ January 2021 Offerings The Company also issued warrants to the placement agent (the “ January 2021 Placement Agent Warrants During the three months ended March 31, 2021, all outstanding shares of Series C Preferred Stock were converted to Common Stock. Q1 2021 Series B Exchanges into the January 2021 Offerings During the three months ended March 31, 2021, pursuant to the Series B Exchange Right, the Company issued an aggregate of 13,501.08 shares of Series C Preferred Stock and warrants to purchase an aggregate of 1,350,066 shares of Common Stock in connection with the exchange of approximately 1,306.30 shares of Series B Preferred Stock. The Company analyzed the exchanges pursuant to the Series B Exchange Right from preferred stock to preferred stock qualitatively and determined that the exchanges result in a substantive change and should be accounted for as an extinguishment. As such, for the three months ended March 31, 2021, the Company recognized an aggregate deemed dividend of approximately $17.6 million as calculated by the difference in the carrying value of the Series B Preferred Stock exchanged and the fair value of the Series C Preferred Stock and January 2021 Investor Warrants issued on each exchange date.

Warrants

Warrants	3 Months Ended
	Mar. 31, 2022
Warrants
Warrants	Note 11 – Warrant activity for the three months ended March 31, 2022 and 2021 was as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ Weighted ​ ​ ​ ​ Average ​ Average ​ ​ Number of ​ Exercise Price ​ Remaining ​ Warrants Per Share Term in Years Outstanding and exercisable on January 1, 2022 5,527,390 ​ $ 9.49 3.95 Issued 11,841,016 ​ 0.76 4.92 Expired (7,366) ​ 49.71 — Exercised (4,848,195) ​ 0.01 4.92 Warrants outstanding and exercisable on March 31, 2022 12,512,845 ​ $ 4.88 4.39 ​ ​ ​ ​ ​ ​ ​ ​ Warrants outstanding and exercisable on January 1, 2021 2,517,722 ​ $ 12.20 4.04 Issued 3,358,519 ​ 7.75 5.12 Expired (2,423) ​ 60.90 — Exercised (919,752) ​ 5.22 2.34 Warrants outstanding and exercisable on March 31, 2021 4,954,066 ​ $ 10.45 4.55 ​ The outstanding warrants expire from 2022 through 2027. In connection with the March 2022 Offering, the Company entered into a warrant amendment agreement with an investor pursuant to which the Company agreed to amend the investor’s existing warrants to purchase up to 1,066,666 shares of the Company’s Common Stock at an exercise price of $8.00 per share issued in January 2021 and warrants to purchase up to 392,927 shares of the Company’s Common stock at an exercise price of $12.10 per share issued in March 2021 (the “Existing Warrants”), in consideration for such investor’s purchase of $9.0 million of securities in the March Offering and payment of $0.0281 per share for each share of common stock issuable upon exercise of the Existing Warrants to (i) lower the exercise price of the Existing Warrants to $1.26 per share and (ii) extend the termination date of the existing Warrants to March 2, 2027. As a result of the change in fair value of the warrant amendment described above, the Company recorded a deemed dividend of approximately $0.595 million in the quarter ended March 31, 2022. During the three months ended March 31, 2022, the Company issued Series C warrants, pre-funded warrants, and placement agent warrants to purchase 11,736,281 shares of the Company’s Common Stock in connection with the March 2022 Offering, as well as Series C warrants to purchase 104,735 shares of the Company’s Common Stock in connection with a Series B Preferred Stock exchange (See Note 10). During the three months ended March 31, 2021, the Company issued warrants, pre-funded warrants, and placement agent warrants to purchase 1,334,664 and 653,789 shares of the Company’s Common Stock in connection with the January 2021 Offerings and the March 2021 Offering, respectively, and warrants to purchase 1,350,066 shares of the Company’s Common Stock in connection with Series B Preferred Stock exchanges (See Note 10). Additionally, on February 8, 2021, warrants to purchase 20,000 shares of the Company’s Common Stock were issued to a consultant at an exercise price of $16.90 per share and expire four years from the date of issuance. The total grant date fair value of these warrants was determined to be approximately $214,000, as calculated using the Black-Scholes model. For the three months ended March 31, 2021, warrants to purchase a total of 5,000 shares of Common Stock vested, with a grant date fair value of approximately $53,000, which was recorded as stock-based compensation as part of general and administrative expense.

Equity Incentive Plan

Equity Incentive Plan	3 Months Ended
	Mar. 31, 2022
Equity Incentive Plan
Equity Incentive Plan	Note 12 – Equity Incentive Plan The Company’s Board and stockholders adopted and approved the Amended and Restated 2014 Omnibus Equity Incentive Plan (the “ 2014 Plan The Company’s Board and stockholders adopted and approved the 2020 Omnibus Equity Incentive Plan (the “ 2020 Plan ISOs As of January 1, 2022, the number of shares of Common Stock available for issuance under the 2020 Plan automatically increased to 2,114,360. As of March 31, 2022, there were an aggregate of 2,114,360 shares available under the 2020 Plan, of which 777,455 shares were issued and outstanding and 1,336,905 shares were available for potential issuances. As of March 31, 2022, there were an aggregate of 301,916 shares available under the 2014 Plan, of which 263,216 shares were issued and outstanding and 38,700 shares are reserved subject to issuance of restricted stock and restricted stock unit awards (“ RSUs During the three months ended March 31, 2022 and 2021, stock option activity under the 2014 Plan and 2020 Plan was as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Average ​ Remaining ​ ​ ​ ​ ​ Number ​ Exercise ​ Contract ​ Intrinsic ​ of Shares Price Life (Years) Value Outstanding at January 1, 2022 439,192 ​ $ 11.58 7.28 ​ $ — Granted 678,392 ​ 1.39 9.11 ​ — Canceled (2,646) ​ 9.68 — ​ — Forfeited ​ (74,267) ​ ​ 3.97 ​ — ​ ​ — Outstanding at March 31, 2022 1,040,671 ​ $ 5.49 8.67 ​ $ — Exercisable at March 31, 2022 380,559 ​ $ 10.60 7.15 ​ $ — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Outstanding at January 1, 2021 407,029 ​ $ 13.80 7.94 ​ $ — Granted 34,365 ​ 10.08 10.00 ​ — Canceled (13,550) ​ 24.46 2.87 ​ — Outstanding at March 31, 2021 427,844 ​ $ 11.89 7.93 ​ $ 1,599,166 Exercisable at March 31, 2021 222,156 ​ $ 14.80 6.67 ​ $ 637,269 ​ During the three months ended March 31, 2022 and 2021, the Board approved the grant of options to purchase 678,392 and 34,365 shares of Common Stock, respectively. All option grants were pursuant to the 2020 Plan. In general, options granted under the 2020 Plan vest monthly over a 36-month period. During the three months ended March 31, 2022 and 2021, stock options to purchase an aggregate of 2,646 and 13,550 shares of Common Stock under the 2020 Plan were cancelled. During the three months ended March 31, 2022, stock options to purchase 74,267 shares of Common Stock were forfeited. For the three months ended March 31, 2022 and 2021, the fair value of each option grant has been estimated on the date of grant using the Black-Scholes Option Pricing Model with the following weighted-average assumptions: ​ ​ ​ ​ ​ ​ ​ ​ ​ 2022 2021 Contractual term (in years) 10 ​ ​ 10 ​ Expected Volatility 90.92 % ​ 84.89 % Risk-free interest rate 1.11 % ​ 1.12 % Expected Dividend yield 0 % ​ 0 % ​ Using the Black-Scholes Option Pricing Model, the estimated weighted average fair value of an option to purchase one share of common stock granted during the three months ended March 31, 2022 and 2021 was $1.37 and $8.28, respectively. As of March 31, 2022, the Company had unrecognized stock-based compensation expense of approximately $1.9 million. Approximately $1.2 million of this unrecognized expense will be recognized over the average remaining vesting term of the stock options of 9.57 As of March 31, 2021, the Company had unrecognized stock-based compensation expense of approximately $1.5 million. Approximately $1.1 million of this unrecognized expense will be recognized over the average remaining vesting term of the stock options of 2.24 years. Approximately $320,000 of this unrecognized expense will vest upon achieving certain clinical and/or corporate milestones. The Company will recognize the expense related to these milestones when the milestones become probable. As of March 31, 2022 and 2021, the Company had 27,500 shares of restricted stock that had not yet vested and unrecognized restricted common stock expense of approximately $394,000. Approximately $197,000 of this unrecognized expense vests upon the first commercial sale in the United States of Adrulipase and approximately $197,000 of this unrecognized expense vests upon the total market capitalization of the Company exceeding $1.0 billion for 20 consecutive trading days. These milestones were not considered probable on March 31, 2022. The total stock-based compensation expense for employees and non-employees is included in the accompanying condensed consolidated statements of operations and as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended March 31, ​ 2022 2021 Research and development ​ $ 46,407 ​ $ 398,312 General and administrative ​ 171,822 ​ 373,928 Total stock-based compensation expense ​ $ 218,229 ​ $ 772,240 ​

Agreements

Agreements	3 Months Ended
	Mar. 31, 2022
Agreements
Agreements	Note 13 – Agreements License Agreement with First Wave Bio, Inc. (FWB) On December 31, 2020, the Company entered into the FWB License Agreement, pursuant to which FWB granted us a worldwide, exclusive right to develop, manufacture, and commercialize FWB’s proprietary immediate release and enema formulations of niclosamide (the “ Niclosamide Product In consideration of the license and other rights granted by FWB, the Company agreed to pay FWB a $9.0 million upfront cash payment due within 10 days, which was paid in January 2021, and was obligated to make an additional payment of $1.25 million due on June 30, 2021, which was paid in July 2021. In addition, the Company was obligated to pay potential milestone payments to FWB totaling up to $37.0 million for each indication, based upon the achievement of specified development and regulatory milestones. In September 2021, the Company achieved a milestone related to clinical development of niclosamide in the COVID-19 field and has expensed $1.0 million in research and development. Under the FWB License Agreement, the Company was obligated to pay FWB royalties as a mid-single digit percentage of net sales of the Niclosamide Product, subject to specified reductions. The Company was also obligated to issue to FWB junior convertible preferred stock, initially convertible into $3.0 million worth of Common Stock based upon the volume weighted average price of the Common Stock for the five-day period immediately preceding the date of the FWB License Agreement, or $9.118 per share, convertible into an aggregate of 329,019 shares of Common Stock. On January 8, 2021, the Company entered into a securities purchase agreement with FWB (the “FWB Purchase Agreement”) to issue junior convertible preferred stock to FWB. Pursuant to the FWB Purchase Agreement, the Company issued to FWB 3,290.1960 shares of Series C Preferred Stock, at an initial stated value of $750.00 per share and a conversion price of $7.50 per share, which is convertible into an aggregate of 32,902 shares of Common Stock. The shares of Series C Preferred Stock automatically converted into Common Stock upon the stockholder approval on February 24, 2021. The FWB Purchase Agreement contains demand and piggyback registration rights with respect to the Common Stock issuable upon conversion. The conversion price of the Series C Preferred Stock was determined to be beneficial and, as a result, the Company recorded a deemed dividend of approximately $230,000 equal to the intrinsic value of the beneficial conversion feature and recognized on the issuance date and recorded as a reduction of income available to common stockholders in computing basic and diluted loss per share. Upon the 2021 Stockholder Approval on February 24, 2021, the Company recognized a change in fair value of approximately $0.5 million based on the difference in fair value of the $3.0 million liability initially recorded pursuant to the FWB License Agreement as of December 31, 2020 and the fair value of approximately $2.5 million of Series C Preferred Stock issued pursuant to the FWB Purchase Agreement to settle the liability. Following the 2021 Stockholder Approval, the shares of Series C Preferred Stock were automatically converted into Common Stock. Upon consummating the Merger on September 13, 2021, the FWB License Agreement was effectively canceled. Mayoly Agreement On March 27, 2019, the Company and Laboratories Mayoly Spinder (“ Mayoly Mayoly APA JDLA

Leases

Leases	3 Months Ended
	Mar. 31, 2022
Leases
Leases	Note 14 – The Company leases its offices under operating leases which are subject to various rent provisions and escalation clauses. The Company is a party to three The Company’s leases expire at various dates through 2026. The escalation clauses are indeterminable and considered not material and have been excluded from minimum future annual rental payments. Lease expense amounted to approximately $28,000 and $52,000, respectively, for the three months ended March 31, 2022 and 2021. The weighted-average remaining lease term and weighted-average discount rate under operating leases as of March 31, 2022 are: ​ ​ ​ ​ ​ ​ ​ March 31, ​ 2022 Lease term and discount rate ​ Weighted-average remaining lease term (years) 4.3 ​ Weighted-average discount rate 7.94 % ​ Maturities of operating lease liabilities as of March 31, 2022, were as follows: ​ ​ ​ ​ ​ 2022 (remainder of year) $ 61,290 2023 ​ 83,691 2024 ​ 86,202 2025 ​ 88,788 Thereafter ​ 60,593 Total lease payments ​ 380,564 Less imputed interest ​ (45,320) Present value of lease liabilities ​ $ 335,244 ​

Net Loss per Common Share

Net Loss per Common Share	3 Months Ended
	Mar. 31, 2022
Net Loss per Common Share
Net Loss per Common Share	Note 15 - Net Loss per Common Share Basic net loss per share is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share reflect, in periods in which they have a dilutive effect, the impact of common shares issuable upon exercise of stock options and warrants and conversion of convertible debt that are not deemed to be anti-dilutive. The dilutive effect of the outstanding stock options and warrants is computed using the treasury stock method. In periods where the Company records a net loss, unvested restricted common stock and potential common stock equivalents are not included in the calculation of diluted net loss per share as their effect would be anti-dilutive. All shares of Common Stock that may potentially be issued in the future are as follows: ​ ​ ​ ​ ​ ​ ​ ​ March 31, 2022 ​ March 31, 2021 ​ (unaudited) (unaudited) Common stock warrants 12,512,845 4,954,066 Stock options 1,040,671 427,844 Convertible preferred stock (1) 717,408 1,236,055 Total shares of common stock issuable 14,270,924 6,617,965 ​ (1) Convertible preferred stock is assumed to be converted at the rate of $7.70 per common share, which is the conversion price as of March 31, 2022.

Employee Benefit Plans

Employee Benefit Plans	3 Months Ended
	Mar. 31, 2021
Employee Benefit Plans
Employee Benefit Plans	Note 16 - Employee Benefit Plans 401(k) Plan Since 2015, the Company has sponsored a multiple employer defined contribution benefit plan, which complies with Section 401(k) of the Internal Revenue Code covering substantially all employees of the Company. All employees are eligible to participate in the plan. Employees may contribute from 1% to 100% of their compensation and the Company matches an amount equal to 100% on the first 6% of the employee contribution and may also make discretionary profit-sharing contributions. Employer contributions under this 401(k) plan amounted to approximately $46,000 and $32,000 for the three months ended March 31, 2022 and 2021, respectively.

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2022
Subsequent Events
Subsequent Events	Note 17 - Subsequent Events The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the financial statements were available to be issued. The Company did not identify any subsequent events that would have required adjustment or disclosure in the financial statements except for the items noted below. Dismissal of Previous Independent Registered Public Accounting Firm On April 27, 2022, the Audit Committee of the Company’s Board of Directors (the “Board”) approved the dismissal of Mazars USA LLP as the Company’s independent registered public accounting firm, effective immediately and the engagement of Marcum LLP as the Company’s new independent registered public accounting firm as of and for the year ending December 31, 2022. RESERVOIR Topline Results and Business Operations Update On April 29, 2022, the Company announced that the Phase 2 RESERVOIR trial examining the safety and efficacy of FW-COV, a proprietary oral formulation of niclosamide, as potential treatment for COVID-19-related GI infections did not meet its efficacy endpoint but FW-COV was demonstrated to be safe with no serious adverse events reported by the more than 150 patients that participated in the trial. As a result of the RESERVOIR trial results, the Company will be reducing its workforce by 20 percent and closing its California office at the end of May 2022 and its facility in Langlade, France. The Company has also suspended payments related to the Company’s acquisition of FWB and is seeking to renegotiate its obligations to the former FWB stockholders; however, no assurance can be given that the Company will be able to restructure those obligations on acceptable terms, if at all. In the event the Company is not able to significantly restructure those obligations, or the Representative prevails in the FWB Action (see Note 17 – The FWB Action Series B Exchange Right Waiver Solicitation Effective May 12, 2022, the holders of 81.3% of the outstanding shares of the Series B Preferred Stock permanently waived for themselves and all other holders of the Series B Preferred Stock the Series B Exchange Right (as defined below) with respect to any Subsequent Financing (as defined below) occurring on or after January 1, 2022 (the “Permanent Waiver”). Holders of Series B Preferred Stock as of the April 27, 2022 record date were entitled to notice of and to consent to the Permanent Waiver (the “Record Holders”). Pursuant to the Certificate of the Designations, Powers, Preferences and Rights creating the Series B Preferred Stock, as filed with the Secretary of State of the State of Delaware on July 16, 2020 (the “Certificate of Designations”), in the event of any issuance by the Company or any of its subsidiaries of Common Stock, or Common Stock equivalents for cash consideration or a combination of units thereof (a “Subsequent Financing”), each holder of the Company’s Series B Preferred Stock had the right, subject to certain exceptions set forth in the Certificate of Designations, at its option, to exchange (in lieu of cash subscription payments) all or some of the Series B Preferred Stock then held (with a value per share of Series B Preferred Stock equal to the stated value of each share of Series B Preferred Stock, or $7,700.00, plus accrued and unpaid dividends thereon, of the Series B Preferred Stock) for any securities or units issued in a Subsequent Financing on a dollar-for-dollar basis (the “Series B Exchange Right”). Pursuant to the terms of the Certificate of Designations, the written consent of the holders of at least a majority of the Series B Preferred Stock outstanding was required to consent to the Permanent Waiver (the “Required Consent”). The Company requested that the Record Holders consent to the Permanent Waiver by executing and delivering a joinder to the Waiver Agreement (as defined below). The execution and delivery of the joinder to the Waiver Agreement was deemed, for purposes of Section 228 of the General Corporation Law of the State of Delaware, to be an action by written consent in lieu of a meeting to approve the Permanent Waiver. The Company’s solicitation of consents to the Permanent Waiver terminated in accordance with its terms at 5:00 p.m., Eastern Time, on May 12, 2022 (the “Expiration Date”). The Record Holders who consented to the Permanent Waiver prior to the Expiration Date are referred to herein as the “Consenting Holders”. The Required Consent has been obtained from the Consenting Holders and the solicitation has terminated in accordance with its terms as of the Expiration Date. The Permanent Waiver was effective immediately upon the Expiration Date and is binding on all holders of the Series B Preferred Stock, including those holders that did not timely consent to the Permanent Waiver prior to the Expiration Date. The Permanent Waiver will also be applicable to any future holder of Series B Preferred Stock. A notation of the Permanent Waiver will be made on the books and records of the Company’s transfer agent and a legend reflecting the Permanent Waiver will be placed on any physical share certificate representing shares of Series B Preferred Stock. Pursuant to the terms of a Waiver Agreement entered into by the Company and the Consenting Holders (the “Waiver Agreement”), the Company has permanently reduced the exercise price of the Series B Warrants originally issued on July 16, 2020 (the “Warrants”) held by the Consenting Holders to $0.25 per share or, in the case of Consenting Holders who are officers and directors of the Company, $0.3294 (the “Exercise Price Reduction”). Only Consenting Holders are entitled to the Exercise Price Reduction. Warrants to purchase an aggregate of approximately 251,742 shares of Common Stock received the Exercise Price Reduction which was effective as of the Expiration Date. ​ Nasdaq Minimum Bid Price Deficiency Notice ​ On May 16, 2022, the Company received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock for the last 30 consecutive business days, the Company is not currently in compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued listing on The Nasdaq Capital Market (the “Notice”). The Company is provided a compliance period of 180 calendar days from the date of the Notice, or until November 14, 2022, to regain compliance with the minimum closing bid requirement. If at any time before November 14, 2022, the closing bid price of the Company’s Common Stock closes at or above $1.00 per share for a minimum of 10 consecutive business days, subject to Nasdaq’s discretion to extend this period to 20 consecutive business days, Nasdaq will provide written notification that the Company has achieved compliance with the minimum bid price requirement, and the matter would be resolved. If the Company does not regain compliance during the compliance period ending November 14, 2022, then Nasdaq may grant the Company a second 180 calendar day period to regain compliance, provided the Company meets the continued listing requirement for market value of publicly-held shares and all other initial listing standards for The Nasdaq Capital Market, other than the minimum closing bid price requirement, and notifies Nasdaq of its intent to cure the deficiency. ​ The FWB Action ​ On May 19, 2022, the Representative filed a complaint against the Company in the Court of Chancery in the State of Delaware (the “ FWB Action ​

Significant Accounting Polici_2

Significant Accounting Policies and Recent Accounting Pronouncements (Policies)	3 Months Ended
	Mar. 31, 2022
Significant Accounting Policies and Recent Accounting Pronouncements
Use of Estimates	Use of Estimates The accompanying unaudited condensed consolidated financial statements are prepared in conformity with GAAP and include certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements (including goodwill and intangible assets), and the reported amounts of revenue and expense during the reporting period, including contingencies. Accordingly, actual results may differ from those estimates.
Reverse Stock Split	Reverse Stock Split On September 13, 2021, the Company effected a reverse stock split, whereby every ten shares of the Company’s issued and outstanding common stock was converted automatically into one issued and outstanding share of common stock, with a corresponding 1-for-10 reduction in the number of authorized shares of common stock, but without any change in the par value per share. All share and per share amounts have been retroactively restated to reflect the reverse stock split.
Reclassifications	Reclassifications Certain prior period balance sheet amounts have been reclassified to conform to the fiscal 2022 presentation.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid investments with maturities of three months or less from date of purchase to be cash equivalents. All cash balances were highly liquid on March 31, 2022, and December 31, 2021, respectively.
Concentrations of Credit Risk	Concentrations of Credit Risk Financial instruments that potentially expose the Company to concentrations of credit risk consist of cash. The Company primarily maintains its cash balances with financial institutions in federally insured accounts in the U.S. The Company may from time to time have cash in banks in excess of FDIC insurance limits. On March 31, 2022, and December 31, 2021, the Company had approximately $4.9 million and $7.5 million, respectively, in one account in the U.S. in excess of these limits. The Company has not experienced any losses to date resulting from this practice. The Company also has exposure to foreign currency risk as its subsidiary in France has a functional currency in Euros.
Fair Value Measurements	Fair Value Measurements The Company follows Accounting Standards Codification ( ASC ( ASC 820 As a basis for considering such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows: Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities; Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions, which reflect those that a market participant would use. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, an instrument’s level within the fair value hierarchy is based on the lowest level of input that is significant to the overall fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the financial instrument. The Company recognizes transfers between levels as if the transfers occurred on the last day of the reporting period.
Foreign Currency Translation	Foreign Currency Translation The Company’s foreign subsidiary has operations denominated in a foreign currency, and assets and liabilities are translated to U.S. dollars, which is the functional currency, at period end exchange rates. Income and expense items are translated at average rates of exchange prevailing during the periods presented. Gains and losses from translation adjustments are accumulated in a separate component of stockholders’ equity.
Goodwill and Intangible Assets	Goodwill and Intangible Assets Goodwill represents the excess of the purchase price of the acquired business over the fair value of amounts assigned to assets acquired and liabilities assumed. Goodwill and other intangible assets with indefinite useful lives are reviewed for impairment annually or more frequently if events or circumstances indicate impairment may be present. Any excess in carrying value over the estimated fair value is charged to results of operations. The Company has not Intangible assets subject to amortization consist of in process research and development, license agreements, and patents reported at the fair value at date of the acquisition less accumulated amortization. Amortization expense is provided using the straight-line method over the estimated useful lives of the assets as follows: Patents 7.2 years The carrying amounts of finite-lived intangible assets are evaluated for recoverability whenever events or changes in circumstances indicate that the Company may be unable to recover the asset’s carrying amount. Given changes in the projected usage of the patents, the Company recognized impairment charges of approximately $2.4 million at December 31, 2021.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets The Company periodically evaluates its long-lived assets for potential impairment in accordance with ASC Topic 360, Property, Plant and Equipment ( ASC 360
Leases	Leases Leases are recorded on the balance sheet as right of use assets and lease obligations.
Research and Development	Research and Development Research and development costs are charged to operations when incurred and are included in operating expense, except for goodwill related to patents. Research and development costs consist principally of compensation of employees and consultants that perform the Company’s research activities, payments to third parties for preclinical and non-clinical activities, expenses with clinical research organizations (“ CROs CDMOs CMC Research and Development – On December 31, 2020, the Company entered into a license agreement (the “ FWB License Agreement On September 13, 2021, the Company completed its acquisition of FWB, which the Company concluded should be accounted for as an asset acquisition rather than a business combination under ASC 805, Business Combinations. The merger was accounted for as an asset acquisition because substantially all the fair value of the assets being acquired are concentrated in a single asset – intellectual property, which does not constitute a business. The former FWB stockholders are also entitled to (i) up to $ 207.0 million of cash milestone payments contingent upon the achievement of specified development, regulatory and sales goals for the use of the acquired assets, and (ii) certain revenue-sharing. During the year ended December 31, 2021, the Company achieved one development milestone pursuant to the FWB License Agreement totaling $1.0 million, which was expensed in research and development. During the year ended December 31, 2021, the Company achieved one development milestone pursuant to the Merger Agreement totaling $2.0 million, which was expensed in research and development. Depending on the status of development at the time a contingent payment is recognized the Company may determine that the payment should be expensed as research and development or be capitalized as an intangible asset. This determination will be based on the facts and circumstances that exist at the time a contingent payment is recognized (See Note 4 for the discussion on the quarter ended March 31, 2022 milestones). Due to the recent topline results of the Phase 2 RESERVOIR COVID-19 GI clinical trial (see Note 1), the Company has suspended payments to the former FWB stockholders and is seeking to renegotiate its obligations to the former FWB stockholders. On May 19, 2022, the Representative filed a complaint against the Company (see Note 17 – The FWB Action
Stock-Based Compensation	Stock-Based Compensation The Company’s board of directors (the “ Board 2014 Plan 2020 Plan ASC 718 For awards with performance conditions that affect their vesting, such as the occurrence of certain transactions or the achievement of certain operating or financial milestones, recognition of fair value of the award occurs when vesting becomes probable. The Company estimates the grant date fair value of stock option awards using the Black-Scholes option-pricing model. The use of the Black-Scholes option-pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the Common Stock consistent with the expected life of the option, risk-free interest rates and expected dividend yields of the Common Stock.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In August 2020, the Financial Accounting Standards Board (the “ FASB SEC In June 2016, the FASB issued accounting pronouncement ASU 2016-13 – Measurement of Credit Losses on Financial Statements. The new standard requires that expected credit losses relating to financial assets measured on an amortized cost basis and available-for-sale debt securities be recorded through an allowance for credit losses. It also limits the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and also requires the reversal of previously recognized credit losses if fair value increases. In November 2019, the FASB issued ASU 2019-10 – Financial Instruments – Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates, which amended the effective date for certain companies. The standard is effective for public companies eligible to be smaller reporting companies for annual and interim periods beginning after December 15, 2022. Early adoption is available. The Company is currently evaluating the potential impact ASU 2016-13, and related updates, will have on its consolidated financial statements and disclosures. The Company has evaluated other recently issued accounting pronouncements and has concluded that the impact of recently issued standards that are not yet effective will not have a material impact on the Company’s financial position or results of operations upon adoption.

Fair Value Disclosures (Tables)

Fair Value Disclosures (Tables)	3 Months Ended
	Mar. 31, 2022
Fair Value Disclosures
Summary of financial instruments	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair Value Measured at Reporting Date ​ ​ ​ ​ ​ ​ ​ ​ Using ​ ​ ​ ​ ​ Carrying ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Amount Level 1 Level 2 Level 3 Fair Value March 31, 2022 (unaudited): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Money market funds ​ $ 501,546 ​ $ 501,546 ​ $ — ​ $ — ​ $ 501,546 Note payable ​ 402,766 ​ — ​ 402,766 ​ — ​ 402,766 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2021: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Money market funds ​ ​ 501,607 ​ ​ 501,607 ​ ​ — ​ ​ — ​ ​ 501,607 Note payable ​ $ 641,236 ​ $ — ​ $ 641,236 ​ $ — ​ $ 641,236

Property, Equipment and Lease_2

Property, Equipment and Leasehold Improvements (Tables)	3 Months Ended
	Mar. 31, 2022
Property, Equipment and Leasehold Improvements
Summary of Property, equipment and leasehold improvements	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, ​ ​ ​ ​ 2022 December 31, ​ ​ (unaudited) ​ 2021 Computer equipment and software ​ $ 11,540 ​ $ 11,540 Office equipment ​ 48,278 ​ 48,278 Leasehold improvements ​ 28,000 ​ 28,000 Total property, plant, and equipment ​ 87,818 ​ 87,818 Less accumulated depreciation ​ (22,025) ​ (14,708) Property, plant and equipment, net ​ $ 65,793 ​ $ 73,110

Intangible Assets and Goodwill

Intangible Assets and Goodwill (Tables)	3 Months Ended
	Mar. 31, 2022
Intangible Assets and Goodwill
Schedule of Patents	​ ​ ​ ​ ​ Common stock issued at signing to Mayoly $ 1,740,959 Due to Mayoly at December 31, 2019 ​ 449,280 Due to Mayoly at December 31, 2020 ​ 393,120 Assumed Mayoly liabilities and forgiveness of Mayoly debt ​ 1,219,386 ​ ​ $ 3,802,745
Schedule of Intangible Assets	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, ​ ​ ​ ​ 2022 December 31, ​ ​ (unaudited) ​ 2021 Patents ​ $ — ​ $ 3,802,745 Less accumulated amortization ​ — ​ (1,450,757) Intangible asset impairment ​ — ​ (2,351,988) Patents, net ​ $ — ​ $ — ​
Schedule of Goodwill	​ ​ ​ ​ ​ ​ Goodwill Balance on January 1, 2021 ​ $ 2,054,048 Foreign currency translation ​ (142,343) Balance on December 31, 2021 ​ 1,911,705 Foreign currency translation ​ (49,636) Balance on March 31, 2022 (unaudited) ​ $ 1,862,069

Accrued Expenses (Tables)

Accrued Expenses (Tables)	3 Months Ended
	Mar. 31, 2022
Accrued Expenses
Summary of accounts payable and accrued expense	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, ​ ​ ​ ​ 2022 December 31, ​ ​ (unaudited) ​ 2021 Professional fees ​ $ 443,030 ​ $ 15,000 Clinical trials ​ ​ 147,842 ​ ​ — Consulting fees ​ ​ 109,260 ​ ​ 104,100 Payroll and benefits ​ ​ 17,382 ​ ​ 274,153 Total accrued expenses ​ $ 717,514 ​ $ 393,253

Other Liabilities (Tables)

Other Liabilities (Tables)	3 Months Ended
	Mar. 31, 2022
Other Liabilities
Schedule of other liabilities	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, ​ ​ ​ ​ 2022 December 31, ​ ​ (unaudited) ​ 2021 Current ​ ​ Lease liabilities ​ $ 70,784 ​ $ 77,989 Other liabilities ​ 18,575 ​ 14,818 Liabilities related to Merger consideration ​ 9,000,000 ​ 8,000,000 Total other current liabilities ​ $ 9,089,359 ​ $ 8,092,807 Long-term ​ ​ Lease liabilities ​ $ 264,460 ​ $ 311,138 Liabilities related to Merger consideration ​ 3,585,044 ​ 7,000,000 Total other long-term liabilities ​ $ 3,849,504 ​ $ 7,311,138

Warrants (Tables)

Warrants (Tables)	3 Months Ended
	Mar. 31, 2022
Warrants
Schedule of warrant transactions	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ Weighted ​ ​ ​ ​ Average ​ Average ​ ​ Number of ​ Exercise Price ​ Remaining ​ Warrants Per Share Term in Years Outstanding and exercisable on January 1, 2022 5,527,390 ​ $ 9.49 3.95 Issued 11,841,016 ​ 0.76 4.92 Expired (7,366) ​ 49.71 — Exercised (4,848,195) ​ 0.01 4.92 Warrants outstanding and exercisable on March 31, 2022 12,512,845 ​ $ 4.88 4.39 ​ ​ ​ ​ ​ ​ ​ ​ Warrants outstanding and exercisable on January 1, 2021 2,517,722 ​ $ 12.20 4.04 Issued 3,358,519 ​ 7.75 5.12 Expired (2,423) ​ 60.90 — Exercised (919,752) ​ 5.22 2.34 Warrants outstanding and exercisable on March 31, 2021 4,954,066 ​ $ 10.45 4.55

Equity Incentive Plan (Tables)

Equity Incentive Plan (Tables)	3 Months Ended
	Mar. 31, 2022
Equity Incentive Plan
Schedule of Stock Option Activity	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Average ​ Remaining ​ ​ ​ ​ ​ Number ​ Exercise ​ Contract ​ Intrinsic ​ of Shares Price Life (Years) Value Outstanding at January 1, 2022 439,192 ​ $ 11.58 7.28 ​ $ — Granted 678,392 ​ 1.39 9.11 ​ — Canceled (2,646) ​ 9.68 — ​ — Forfeited ​ (74,267) ​ ​ 3.97 ​ — ​ ​ — Outstanding at March 31, 2022 1,040,671 ​ $ 5.49 8.67 ​ $ — Exercisable at March 31, 2022 380,559 ​ $ 10.60 7.15 ​ $ — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Outstanding at January 1, 2021 407,029 ​ $ 13.80 7.94 ​ $ — Granted 34,365 ​ 10.08 10.00 ​ — Canceled (13,550) ​ 24.46 2.87 ​ — Outstanding at March 31, 2021 427,844 ​ $ 11.89 7.93 ​ $ 1,599,166 Exercisable at March 31, 2021 222,156 ​ $ 14.80 6.67 ​ $ 637,269
Stock Options-pricing Model with Weighted Average Assumptions	​ ​ ​ ​ ​ ​ ​ ​ ​ 2022 2021 Contractual term (in years) 10 ​ ​ 10 ​ Expected Volatility 90.92 % ​ 84.89 % Risk-free interest rate 1.11 % ​ 1.12 % Expected Dividend yield 0 % ​ 0 %
Schedule of stock-based compensation expense	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended March 31, ​ 2022 2021 Research and development ​ $ 46,407 ​ $ 398,312 General and administrative ​ 171,822 ​ 373,928 Total stock-based compensation expense ​ $ 218,229 ​ $ 772,240

Leases (Tables)

Leases (Tables)	3 Months Ended
	Mar. 31, 2022
Leases
Weighted Average Remaining Lease Term and Discount Rate Under Operating Lease	​ ​ ​ ​ ​ ​ ​ March 31, ​ 2022 Lease term and discount rate ​ Weighted-average remaining lease term (years) 4.3 ​ Weighted-average discount rate 7.94 %
Maturities of Operating Lease Liabilities	Maturities of operating lease liabilities as of March 31, 2022, were as follows: ​ ​ ​ ​ ​ 2022 (remainder of year) $ 61,290 2023 ​ 83,691 2024 ​ 86,202 2025 ​ 88,788 Thereafter ​ 60,593 Total lease payments ​ 380,564 Less imputed interest ​ (45,320) Present value of lease liabilities ​ $ 335,244

Net Loss per Common Share (Tabl

Net Loss per Common Share (Tables)	3 Months Ended
	Mar. 31, 2022
Net Loss per Common Share
Schedule of Common Stock that may potentially be issued in the future	​ ​ ​ ​ ​ ​ ​ ​ March 31, 2022 ​ March 31, 2021 ​ (unaudited) (unaudited) Common stock warrants 12,512,845 4,954,066 Stock options 1,040,671 427,844 Convertible preferred stock (1) 717,408 1,236,055 Total shares of common stock issuable 14,270,924 6,617,965 ​ (1) Convertible preferred stock is assumed to be converted at the rate of $7.70 per common share, which is the conversion price as of March 31, 2022.

The Company and Basis of Pres_2

The Company and Basis of Presentation (Details) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
The Company and Basis of Presentation
Cash and cash equivalents	$ 5,694,988	$ 8,248,684
Accumulated deficit	(163,530,886)	$ (153,904,047)
working capital	$ 7,700,000

Significant Accounting Polici_3

Significant Accounting Policies and Recent Accounting Pronouncements (Details) - USD ($) $ in Thousands	Sep. 13, 2021	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Number of shares recuded due to reverse stock split	10
Cash in US banks in excess of FDIC insurance limits		$ 4,900	$ 7,500
Finite-Lived Intangible Asset, Useful Life (Year)		7 years 2 months 12 days
Intangible asset impairment			2,400
Asset impairment charges		$ 0
First Wave License Agreement [Member]
Asset acquisition consideration transferred				$ 13,300
Payments to Acquire Intangible Assets				10,300
Cash consideration		$ 3,000		$ 3,000
Asset acquisition cash milestone payments			1,000
FWB [Member] | Maximum [Member]
Asset acquisition cash milestone payments	$ 207,000
Merger Agreement [Member]
Asset acquisition cash milestone payments			$ 2,000

Fair Value Disclosures (Details

Fair Value Disclosures (Details) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Cash and cash equivalents	$ 5,694,988	$ 8,248,684
Note payable	402,766	641,236
Carrying Amount
Note payable	402,766	641,236
Fair Value, Inputs, Level 2
Note payable	402,766	641,236
Money Market Funds
Cash and cash equivalents	501,546	501,607
Money Market Funds | Carrying Amount
Cash and cash equivalents	501,546	501,607
Money Market Funds | Fair Value, Inputs, Level 1
Cash and cash equivalents	$ 501,546	$ 501,607

Asset Acquisition (Details)

Asset Acquisition (Details) - USD ($)	Nov. 15, 2021	Oct. 29, 2021	Sep. 13, 2021	Mar. 31, 2022	Aug. 31, 2022	Jul. 31, 2023	Dec. 31, 2021	Mar. 31, 2021
Shares issued price per share (in dollars per share)				$ 1.375				$ 12.725
First Wave Bio Inc [Member]
Payment to acquire			$ 3,000,000
Asset acquired equity issued (in shares)			624,025
Asset acquisition total purchase price			$ 22,000,000
Asset acquisition consideration transferred liabilities incurred			$ 8,000,000	$ 7,000,000
Maximum term for the payment of purchase price			45 days
Asset Acquisition, Potential Milestone Payments				0			$ 2,000,000
Asset acquisition consideration transferred				$ 2,400,000			7,000,000
Cash consideration			$ 4,000,000
Asset acquired equity issued (in shares)			624,025
Shares issued price per share (in dollars per share)			$ 6.41
First Wave Bio Inc [Member] | Research and development
Non-contingent purchase price							21,300,000
First Wave Bio Inc [Member] | General and administrative expense.
Consideration transaction cost							$ 900,000
First Wave Bio Inc [Member] | Former Stockholders
Milestone payment		$ 2,000,000
Awarded to other party		$ 8,000,000
First Wave Bio Inc [Member] | Development Achievement Threshold [Member]
Asset Acquisition, Potential Milestone Payments			$ 207,000,000
Percentage of cash milestone payments			25.00%
First Wave Bio Inc [Member] | Patent Infringement [Member]
Percentage of cash consideration			10.00%
First Wave Bio Inc [Member] | Settlement Agreement
Milestone payment	$ 2,000,000
Awarded to other party	$ 15,000,000
Percentage of amount on the transactions consummated by the company	10.00%
Specified amount of transactions for applying percentage	$ 10,000,000
Stock cancelled during period, shares, acquisitions (in shares)	332,913
First Wave Bio Inc [Member] | Settlement Agreement | Forecast
Payment of periodic installments					$ 500,000	$ 1,000,000

Property, Equipment and Lease_3

Property, Equipment and Leasehold Improvements - Property (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Total property, plant, and equipment	$ 87,818		$ 87,818
Less accumulated depreciation	(22,025)		(14,708)
Property, plant and equipment, net	65,793		73,110
Depreciation expense	7,317	$ 1,000
Computer Equipment And Software [Member]
Total property, plant, and equipment	11,540		11,540
Office Equipment [Member]
Total property, plant, and equipment	48,278		48,278
Leasehold Improvements [Member]
Total property, plant, and equipment	$ 28,000		$ 28,000

Intangible Assets and Goodwil_2

Intangible Assets and Goodwill - Patents (Details) - USD ($)	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Patents	$ 3,800,000	$ 3,802,745
Common Stock Issued At Signing To Mayoly [Member]
Patents				$ 1,740,959
Mayoly [Member]
Patents			$ 393,120	$ 449,280
Assumed Mayoly Liabilities And Forgiveness Of Mayoly Debt [ Member]
Patents		$ 1,219,386

Intangible Assets and Goodwil_3

Intangible Assets and Goodwill - Intangible Assets (Details)	Dec. 31, 2021USD ($)
Intangible Assets and Goodwill
Patents	$ 3,802,745
Less accumulated amortization	(1,450,757)
Intangible asset impairment	$ (2,351,988)

Intangible Assets and Goodwil_4

Intangible Assets and Goodwill (Details) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2021	Dec. 31, 2021
Intangible Assets and Goodwill
Amortization expense	$ 132,000
Intangible asset impairment		$ 2,400,000

Intangible Assets and Goodwil_5

Intangible Assets and Goodwill - Goodwill (Details) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Intangible Assets and Goodwill
Balance	$ 1,911,705	$ 2,054,048
Foreign currency translation	(49,636)	(142,343)
Balance	$ 1,862,069	$ 1,911,705

Accrued Expenses (Details)

Accrued Expenses (Details) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Accrued Expenses
Professional fees	$ 443,030	$ 15,000
Clinical trials	147,842
Consulting fees	109,260	104,100
Payroll and benefits	17,382	274,153
Total accrued expenses	$ 717,514	$ 393,253

Note Payable (Details)

Note Payable (Details) - USD ($)	Nov. 30, 2021	Mar. 31, 2022	Dec. 31, 2021
Note payables		$ 403,000	$ 641,000
Financing Agreement for Directors and Officer's Liability Insurance [Member]
Debt Instrument, term	9 months
Debt Instrument, face amount	$ 957,000
Debt instrument, interest Rate	3.99%
Debt instrument, periodic payment	$ 81,000

Other Liabilities (Details)

Other Liabilities (Details) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Other Liabilities, Current [Abstract]
Lease liabilities	$ 70,784	$ 77,989
Other liabilities	18,575	14,818
Liabilities related to Merger consideration	9,000,000	8,000,000
Total other current liabilities	9,089,359	8,092,807
Long-term
Lease liabilities	264,460	311,138
Liabilities related to Merger consideration	3,585,044	7,000,000
Total other long-term liabilities	$ 3,849,504	$ 7,311,138

Capital Stock (Details)

Capital Stock (Details) - USD ($)	Feb. 07, 2022	Sep. 13, 2021	May 26, 2021	Mar. 31, 2022	Mar. 31, 2021	Jan. 31, 2021	Nov. 30, 2019	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Mar. 31, 2022	Feb. 08, 2021
Common Stock, Shares Authorized (in shares)				50,000,000				50,000,000		50,000,000	50,000,000
Common Stock, Par or Stated Value Per Share (in dollars per share)				$ 0.0001				$ 0.0001		$ 0.0001	$ 0.0001
Preferred Stock, Shares Authorized (in shares)				10,000,000				10,000,000			10,000,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share)				$ 0.0001				$ 0.0001			$ 0.0001
Number of shares recuded due to reverse stock split		10
Common Stock, Shares, Issued, Total (in shares)				21,548,835				21,548,835		14,855,848	21,548,835
Common Stock, Shares, Outstanding, Ending Balance (in shares)				21,548,835				21,548,835		14,855,848	21,548,835
Preferred Stock, Convertible, Conversion Price (in dollars per share)				$ 7.70				$ 7.70			$ 7.70
Shares Issued, Price Per Share (in dollars per share)				1.375	$ 12.725			1.375	$ 12.725		1.375
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)					1,350,066				1,350,066			20,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)				$ 1.26	$ 1.26			$ 1.26	$ 1.26		$ 1.26	$ 16.90
Warrants and Rights Outstanding, Term (Year)				5 years	5 years			5 years	5 years		5 years	4 years
Proceeds from Issuance of Common Stock								$ 7,972,091	$ 9,059,290
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)				1				1			1
Issuance of common stock, pre-funded warrants and warrants in registered direct offering, net of issuance costs (in shares)								1,650,000	580,000
Pre-funded warrants to purchase of common stock									205,854
Class of Warrant or Rights, Investor and Pre_funded Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)					392,927				392,927
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)					$ 0.10				$ 0.10
January 2021 Investor Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)						1,066,666
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)						$ 8
Series C Warrants
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)				6,498,195				6,498,195			6,498,195
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)				$ 1.26				$ 1.26			$ 1.26
Warrants and Rights Outstanding, Term (Year)				5 years				5 years			5 years
Pre-Funded Warrant
Shares Issued, Price Per Share (in dollars per share)				$ 1.385				$ 1.385			$ 1.385
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)				4,848,195				4,848,195			4,848,195
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)				$ 1.73				$ 1.73			$ 1.73
Warrants and Rights Outstanding, Term (Year)				5 years				5 years			5 years
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)				1				1			1
January 2021 Placement Agent Warrants [Member]
Shares Issued, Price Per Share (in dollars per share)					$ 7.50				$ 7.50
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)					74,667				74,667
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)					$ 9.375				$ 9.375
Percentage Of Common Stock Issued In Offering									7.00%
March 2021 Placement Agent Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)					55,008				55,008
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)					$ 15.906				$ 15.906
Equity Offering, Price Per Share (in dollars per share)					$ 12.725				$ 12.725
Percentage of warrants issued									7.00%
Percentage of exercise price of warrants									125.00%
Series C Preferred Stock Converted into Common Stock [Member]
Issuance of stock upon conversion of securities (in shares)									2,561,544
Conversion of Stock, Shares Converted (in shares)									2,746
Issuance of stock upon conversion of securities									$ 20,600,000
Conversion of Stock, Amount Converted, Accrued Dividends									$ 76,000
Series B Preferred Stock Converted into Common Stock [Member]
Conversion of Stock, Shares Issued (in shares)									258,278
Conversion of Stock, Shares Converted (in shares)									26
Issuance of stock upon conversion of securities									$ 2,000,000
Conversion of Stock, Amount Converted, Accrued Dividends									$ 3,000
Series B Preferred Stock Exchanged for Common Shares [Member]
Conversion of Stock, Shares Converted (in shares)				17.05
Issuance of stock upon conversion of securities				$ 131,000
Conversion of Stock, Amount Converted, Accrued Dividends				$ 14,000
Series B Preferred Stock Exchanged for Common Shares [Member] | Series C Warrants
Conversion of Stock, Shares Issued (in shares)				104,735
Consultants [Member]
Stock Issued During Period, Shares, Settlement (in shares)								90,057	57,530
Stock Issued During Period, Value, Settlement								$ 119,000	$ 891,000
Former Investor Bank [Member]
Stock Issued During Period, Value, Settlement					$ 94,000
Shares issued for settlement (in shares)									7,500
Equity Line Agreement [Member] | Lincoln Park [Member]
Common Stock, Shares, Issued, Total (in shares)							48,716
Fair value of commitment shares on grant date							$ 297,000
Term of Equity Line Agreement for Sale of Shares							30 months
Stock Issued During Period, Value, New Issues											$ 0
Stock Purchase Agreement, Committed Shares, Remaining Value								$ 14,000,000
Market Agreement [Member] | H C Wainwright Co L L C [Member]
Stock Issued During Period, Shares, New Issues (in shares)										5,333,345
Stock issuance costs										$ 601,000
Proceeds from Issuance of Common Stock										$ 19,200,000
At The Market Offering Agreement [Member] | Wainwright [Member]
Stock Sales Agreement, Commission on Shares Sold, Percentage			3.00%
Stock Sales Agreement, Number of Shares Authorized (in shares)			50,000,000
January 2021 Offering
Proceeds from Issuance or Sale of Equity, Total									$ 7,100,000
Direct offering | Pre-Funded Warrant
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)				389,891				389,891			389,891
Class of Warrant or Right, Issued, Percentage of Common Stock Issued in Offering								6.00%
Warrants [Member]
Class of Warrant or Right, Exercised During Period (in shares)									919,752
Pre-Funded Warrants [Member]
Conversion of Stock, Shares Issued (in shares)				4,848,195
Class of Warrant or Right, Exercised During Period (in shares)									399,187
Shares Issued, Price Per Share (in dollars per share)				$ 0.01				$ 0.01			$ 0.01
Series B Preferred Stock [Member]
Preferred Stock, Shares Authorized (in shares)				5,194.81				5,194.81		5,194.81	5,194.81
Issuance of stock upon conversion of securities (in shares)									1,306.30
Preferred Stock, Par or Stated Value Per Share (in dollars per share)				$ 0.0001				$ 0.0001		$ 0.0001	$ 0.0001
Preferred Stock, Shares Issued, Total (in shares)				645.21				645.21		662.25	645.21
Preferred stock, shares outstanding (in shares)				645.20				645.20		662.25	645.20
Preferred Stock, Shares Outstanding, Ending Balance (in shares)				645.20				645.20		662.25	645.20
Series B Preferred Stock [Member] | Waiver
Preferred Stock, Par or Stated Value Per Share (in dollars per share)	$ 0.0001
Cash waiver fee (in percentage)	10.00%
Preferred stock, alternate redemption value	$ 7,700
Value of preferred stock agreed to be waived with holders of preferred stock	2,880,000
Value of preferred stock agreed to be waived with insiders	$ 474,000
Waiver fee paid								$ 233,000
Series C Preferred Stock [Member]
Preferred Stock, Shares Authorized (in shares)				57,000				57,000		57,000	57,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share)				$ 0.0001				$ 0.0001		$ 0.0001	$ 0.0001
Preferred Stock, Shares Issued, Total (in shares)				0				0		0	0
Convertible Preferred Stock, Shares Issued upon Conversion (in shares)					13,501.08				13,501.08
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)					1,350,066				1,350,066
Preferred stock, shares outstanding (in shares)				0				0		0	0
Preferred Stock, Shares Outstanding, Ending Balance (in shares)				0				0		0	0
Deemed dividends on preferred stock issuances									$ 17,600,000
Series C Preferred Stock [Member] | January 2021 Placement Agent Warrants [Member]
Percentage of effective purchase price per share of preferred stock									125.00%
Series C Preferred Stock [Member] | January 2021 Registered Direct Offering [Member]
Preferred Stock, Convertible, Conversion Price (in dollars per share)					$ 7.50				$ 7.50
Stock Issued During Period, Shares, New Issues (in shares)									5,333.33
Shares Issued, Price Per Share (in dollars per share)					$ 750				$ 750
Convertible Preferred Stock, Shares Issued upon Conversion (in shares)					533,333				533,333
Series C Preferred Stock [Member] | January 2021 Private Placement [Member]
Stock Issued During Period, Shares, New Issues (in shares)						5,333.33
Common Stock [Member]
Stock Issued During Period, Shares, Exercise of Warrants (in shares)									912,807
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)					$ 12.10				$ 12.10
Common Stock [Member] | Pre-Funded Warrant
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)				$ 0.01				$ 0.01			$ 0.01
Common Stock [Member] | Waiver
Common Stock, Par or Stated Value Per Share (in dollars per share)	$ 0.0001
Maximum [Member] | Equity Line Agreement [Member] | Lincoln Park [Member]
Issuance of available Equity Line Agreement							$ 15,000,000

Warrant Transactions (Details)

Warrant Transactions (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Feb. 08, 2021	Jan. 31, 2021
Number of Warrants [Roll Forward]
Warrants outstanding and exercisable, beginning (in shares)	5,527,390	2,517,722
Issued (in shares)	11,841,016	3,358,519
Expired (in shares)	(7,366)	(2,423)
Exercised (in shares)	(4,848,195)	(919,752)
Warrants outstanding and exercisable, ending (in shares)	12,512,845	4,954,066
Exercise Price Per Share [Roll Forward]
Warrants outstanding and exercisable, beginning (in dollars per share)	$ 9.49	$ 12.20
Issued (in dollars per share)	0.76	7.75
Expired (in dollars per share)	49.71	60.90
Exercised (in dollars per share)	0.01	5.22
Warrants outstanding and exercisable, ending (in dollars per share)	4.88	10.45
Weighted Average Price [Roll Forward]
Warrants outstanding and exercisable, beginning (in dollars per share)	$ 3.95	$ 4.04
Issued (in dollars per share)	4.92	5.12
Expired (in dollars per share)	0	0
Exercised (in dollars per share)	4.92	2.34
Warrants outstanding and exercisable, ending (in dollars per share)	$ 4.39	$ 4.55
Warrants to purchase of stock		1,350,066	20,000
Warrant exercise price	1.26	$ 1.26	$ 16.90
Shares Issued, Price Per Share (in dollars per share)	$ 1.375	12.725
Deemed dividend	$ 595
Warrant Amendment Agreement [Member]
Weighted Average Price [Roll Forward]
Warrant exercise price		$ 12.10		$ 8
March Offering [Member]
Weighted Average Price [Roll Forward]
Consideration for purchase of securities		$ 9,000
Shares Issued, Price Per Share (in dollars per share)		$ 0.0281
Maximum [Member] | Warrant Amendment Agreement [Member]
Weighted Average Price [Roll Forward]
Warrants to purchase of stock		392,927		1,066,666

Warrant Transactions - Series C

Warrant Transactions - Series C, Pre-funded and Placement agent Warrants (Details) - USD ($)	Feb. 08, 2021	Mar. 31, 2022	Mar. 31, 2021
Class of Warrant or Right [Line Items]
Warrants to purchase of Common stock	20,000		1,350,066
Warrant exercise price	$ 16.90	$ 1.26	$ 1.26
Warrants term	4 years	5 years	5 years
Stock-based compensation		$ 218,229	$ 772,240
General and administrative expense.
Class of Warrant or Right [Line Items]
Stock-based compensation		$ 171,822	$ 373,928
Series C warrants, pre-funded warrants, and placement agent warrants
Class of Warrant or Right [Line Items]
Warrants to purchase of Common stock		11,736,281
Series C Warrants
Class of Warrant or Right [Line Items]
Warrants to purchase of Common stock		6,498,195
Warrant exercise price		$ 1.26
Warrants term		5 years
Series C Warrants | March 2022 Offering [Member]
Class of Warrant or Right [Line Items]
Warrants to purchase of Common stock		104,735
Warrants, pre-funded warrants, and placement agent warrants | January 2021 Offering
Class of Warrant or Right [Line Items]
Warrants to purchase of Common stock			1,334,664
Warrants, pre-funded warrants, and placement agent warrants | March 2021 Offering
Class of Warrant or Right [Line Items]
Warrants to purchase of Common stock			653,789
Warrants [Member]
Class of Warrant or Right [Line Items]
Grant date fair value of warrants	$ 214,000
Warrants vested	5,000
Warrants [Member] | General and administrative expense.
Class of Warrant or Right [Line Items]
Stock-based compensation	$ 53,000

Equity Incentive Plan - Additio

Equity Incentive Plan - Additional information (Details)	Sep. 11, 2020shares	Mar. 31, 2022USD ($)shares	Mar. 31, 2022USD ($)$ / sharesshares	Mar. 31, 2021USD ($)$ / sharesshares	Mar. 31, 2022USD ($)shares	Jan. 31, 2022shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted			678,392	34,365
Weighted average fair value of warrants granted (in dollars per share) | $ / shares			$ 1.37	$ 8.28
Unrecognized stock-based compensation expense | $		$ 1,900,000	$ 1,900,000	$ 1,500,000	$ 1,900,000
Average remaining vesting term of the stock options (in years)		9 years 6 months 25 days
Vested during the period (in shares)			27,500	27,500
Consecutive trading days | $					20
Unrecognized expense vests | $			$ 197,000	$ 197,000
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized stock-based compensation expense | $		$ 1,000,000,000	1,000,000,000	1,000,000,000	$ 1,000,000,000
Vesting Over Remaining Term
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized stock-based compensation expense | $		1,200,000	$ 1,200,000	$ 1,100,000	1,200,000
Average remaining vesting term of the stock options (in years)			0 years	2 years 2 months 26 days
Initiating Phase 3 Trial in US [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized stock-based compensation expense | $		730,000	$ 730,000		730,000
Performance Based Milestone [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized stock-based compensation expense | $				$ 320,000
Incentive Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted			1,500,000
Restricted Stock | Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized stock-based compensation expense | $		$ 394,000	$ 394,000	$ 394,000	$ 394,000
2020 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available under equity incentive plan (in shares)	1,000,000	2,114,360	2,114,360		2,114,360	2,114,360
Percentage of common stock reserved for issuance equity incentive plan	10.00%
Shares reserved subject to issuance (in shares)		1,336,905	1,336,905		1,336,905
Options to purchase shares of common stock (in shares)		777,455	777,455		777,455
Vesting period			36 months
Options cancelled			2,646	13,550
Options forfeited			74,267
Equity Incentive Plan2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available under equity incentive plan (in shares)		301,916	301,916		301,916
Options to purchase shares of common stock (in shares)		263,216	263,216		263,216
The 2014 Omnibus Equity Incentive Plan | Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved subject to issuance (in shares)		38,700	38,700		38,700

Equity Incentive Plan - Stock o

Equity Incentive Plan - Stock option activity (Details) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
Numbers of shares
Granted	678,392	34,365
Incentive Stock Options
Numbers of shares
Granted	1,500,000
Equity Incentive Plan 2014 And Plan 2020 | Incentive Stock Options
Numbers of shares
Number of Shares, Beginning (in shares)	439,192	407,029	407,029
Granted	678,392	34,365
Canceled	(2,646)
Forfeited	(74,267)	(13,550)
Number of Shares, Ending (in shares)	1,040,671	427,844	439,192	407,029
Exercisable (in shares)	380,559	222,156
Average Exercise Price
Average Exercise Price, Beginning (in dollars per share)	$ 11.58	$ 13.80	$ 13.80
Average Exercise Price, Granted	1.39	10.08
Average Exercise Price, Canceled	9.68
Average Exercise Price, Forfeited	3.97	24.46
Average Exercise Price, Ending (in dollars per share)	5.49	11.89	$ 11.58	$ 13.80
Exercisable, average exercise price (in dollars per share)	$ 10.60	$ 14.80
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Stock option outstanding, remaining contractual life (Year)	8 years 8 months 1 day	7 years 11 months 4 days	7 years 3 months 10 days	7 years 11 months 8 days
Granted during the period remaining contractual life (Year)	9 years 1 month 9 days	10 years
canceled during the period remaining contractual life (Year)	0 years
Forefeited during the period remaining contractual life (Year)	0 years	2 years 10 months 13 days
Exercisable, Remaining Contract Life (Years)	7 years 1 month 24 days	6 years 8 months 1 day
Stock options outstanding, intrinsic value		$ 1,599,166
Exercisable, intrinsic value		$ 637,269

Equity Incentive Plan - Weighte

Equity Incentive Plan - Weighted-average assumptions (Details) - Stock Option	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Contractual term (in years)	10 years	10 years
Expected Volatility	90.92%	84.89%
Risk-free interest rate	1.11%	1.12%
Expected Dividend yield	0.00%	0.00%

Equity Incentive Plan - Total s

Equity Incentive Plan - Total stock-based compensation expense (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 218,229	$ 772,240
Research and development
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	46,407	398,312
General and administrative expense.
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 171,822	$ 373,928

Agreements (Details)

Agreements (Details) - USD ($)	Sep. 13, 2021	Feb. 24, 2021	Jan. 08, 2021	Jan. 31, 2021	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2020	Jun. 30, 2021
Research and Development Expense, Total					$ 4,976,517	$ 2,516,027
Preferred Stock, Convertible, Conversion Price (in dollars per share)					$ 7.70
Shares Issued, Price Per Share (in dollars per share)					$ 1.375	$ 12.725
Fair Value, Option, Changes in Fair Value, Gain (Loss)						$ 532,653
Deemed Dividends, Preferred Stock Issuances						$ 4,507,125
Series C Preferred Stock [Member]
Convertible Preferred Stock, Shares Issued upon Conversion (in shares)						13,501.08
Series C Preferred Stock [Member] | First Wave Purchase Agreement [Member]
Deemed Dividends on Preferred Stock Issuances			$ 230,000
First Wave Bio Inc [Member]
Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable	$ 4,000,000
Shares Issued, Price Per Share (in dollars per share)	$ 6.41
First Wave License Agreement [Member]
Upfront cash payment to be paid in first ten days				$ 9,000,000
Asset Acquisition, Additional Cash to be Paid								$ 1,250,000
Asset Acquisition, Contingent Consideration, Liability, Total					$ 37,000,000
Research and Development Expense, Total					1,000,000
Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable					$ 3,000,000		$ 3,000,000
Period for conversion of common stock					5 days
Fair Value, Option, Changes in Fair Value, Gain (Loss)		$ 500,000
Convertible Preferred Stock, Nonredeemable or Redeemable, Issuer Option, Value							$ 3,000,000
Redeemable Noncontrolling Interest, Equity, Common, Fair Value		$ 2,500,000
First Wave License Agreement [Member] | First Wave Purchase Agreement [Member]
Upfront cash payment term				10 days
First Wave License Agreement [Member] | Convertible Preferred Stock [Member]
Preferred Stock, Convertible, Conversion Price (in dollars per share)					$ 9.118
Convertible Preferred Stock, Shares Issued upon Conversion (in shares)					329,019
First Wave License Agreement [Member] | Series C Preferred Stock [Member]
Preferred Stock, Convertible, Conversion Price (in dollars per share)			$ 7.50
Convertible Preferred Stock, Shares Issued upon Conversion (in shares)			32,902
Stock Issued During Period, Shares, New Issues (in shares)			3,290.1960
Shares Issued, Price Per Share (in dollars per share)			$ 750

Leases (Details)

Leases (Details)	3 Months Ended
	Mar. 31, 2022USD ($)ft²	Mar. 31, 2021USD ($)
Lessee, Operating Lease, Term of Contract (Month)	63 months
Operating Lease, Expense | $	$ 28,000	$ 52,000
Office Space at 777 Yamato Road, Suite 502, Boca Raton, FL 33431 [Member]
Area of Real Estate Property (Square Foot) | ft²	3,472

Leases - weighted-average remai

Leases - weighted-average remaining lease term (Details)	Mar. 31, 2022
Leases
Weighted-average remaining lease term (years) (Year)	4 years 3 months 18 days
Weighted-average discount rate	7.94%

Leases - Maturities of operatin

Leases - Maturities of operating lease liabilities (Details)	Mar. 31, 2022USD ($)
Leases
2022	$ 61,290
2023	83,691
2024	86,202
2025	88,788
Thereafter	60,593
Total lease payments	380,564
Less imputed interest	(45,320)
Present value of lease liabilities	$ 335,244

Net Loss per Common Share (Deta

Net Loss per Common Share (Details) - $ / shares	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)	14,270,924	6,617,965
Preferred Stock, Convertible, Conversion Price (in dollars per share)	$ 7.70
Warrants.
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)	12,512,845	4,954,066
Stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)	1,040,671	427,844
Convertible preferred stock (1)
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)	717,408	1,236,055

Employee Benefit Plans (Details

Employee Benefit Plans (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Defined Contribution Plan, Employers Matching Contribution, Annual Vesting Percentage	6.00%
Defined Benefit Plan, Plan Assets, Contributions by Employer	$ 46,000	$ 32,000
Minimum [Member]
Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent	1.00%
Maximum [Member]
Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent	100.00%

Subsequent Events (Details)

Subsequent Events (Details)	Nov. 14, 2022$ / shares	May 16, 2022$ / shares	May 12, 2022USD ($)$ / sharesshares	Mar. 31, 2022USD ($)$ / sharesshares	Dec. 31, 2021$ / sharesshares	Mar. 31, 2021$ / sharesshares	Feb. 08, 2021$ / shares	Dec. 31, 2020shares
Subsequent Event [Line Items]
Exercise Price Reduction				$ 1.26		$ 1.26	$ 16.90
Purchase of aggregate common stock | shares				12,512,845	5,527,390	4,954,066		2,517,722
Consecutive trading days | $				20
Common stock, par value (in dollars per share)				$ 0.0001	$ 0.0001
Subsequent Event
Subsequent Event [Line Items]
Consecutive trading days	180	30
Common stock, par value (in dollars per share)	$ 1	$ 1
Subsequent Event | Waiver | Officers and Directors
Subsequent Event [Line Items]
Exercise Price Reduction			$ 0.3294
Subsequent Event | Waiver | Warrants.
Subsequent Event [Line Items]
Exercise Price Reduction			$ 0.25
Series B Preferred Stock [Member] | Subsequent Event | Waiver
Subsequent Event [Line Items]
Percentage of outstanding shares			81.30%
Accrued and unpaid dividends | $			$ 7,700
Purchase of aggregate common stock | shares			251,742